The National Comprehensive Cancer Network (NCCN) released the new Genetic/Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on August 8th, 2024. Updates include gynecologic risk and preventive surgery considerations for MLH1, MSH6, MSH2, and PMS2 carriers. You can check out the full guidelines by creating a FREE account at:https://www.nccn.org/professionals/physician_gls/pdf/genetics_ceg.pdf
Tag: Social Media
Permanent link to this article: https://inheritedcancer.net/post91824/
ICARE Social Media Post September 2024
NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update – VERSION 2
ICARE Social Media Post September 2024
NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update – VERSION 2
The National Comprehensive Cancer Network (NCCN) released the new Genetic/Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on August 8th, 2024. Updates include ⤸ You can check out the full guidelines by creating a FREE account at:https://www.nccn.org/professionals/physician_gls/pdf/genetics_ceg.pdf
Permanent link to this article: https://inheritedcancer.net/post91424/
ICARE Social Media Post September 2024
NCCN Breast, Ovarian, and Pancreatic Cancer Guidelines Update
ICARE Social Media Post September 2024
NCCN Breast, Ovarian, and Pancreatic Cancer Guidelines Update
The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. Some updates include ⤸ To read more, you can check out the full guidelines by creating a FREE account at:https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf
Permanent link to this article: https://inheritedcancer.net/post91224/
ICARE Social Media Post September 2024
NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update
ICARE Social Media Post September 2024
NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update
The National Comprehensive Cancer Network (NCCN) released the new Genetic Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on August 8th, 2024. Updates include ⤸• Endometrial cancer recommendations included throughout• Hereditary Diffuse Gastric Cancer section added (HGAST-1)• Gynecologic risk and preventive surgery considerations for those with Lynch Syndrome• Use of hormone replacement treatment following …
Permanent link to this article: https://inheritedcancer.net/post90324/
ICARE Social Media Post August 2024
ICARE Overview Video
ICARE Social Media Post August 2024
ICARE Overview Video
Learn more about the Inherited Cancer Registry (ICARE) by watching an exciting presentation by student researcher, Reagan Sellers, who provides information about the history of ICARE, what being an ICARE participant entails, our various education and engagement efforts, and the focused research studies being conducted through ICARE. Check out the full video on our YouTube …
Permanent link to this article: https://inheritedcancer.net/post82824/
ICARE Social Media Post August 2024
BRCA1/2 carriers: Melanoma Risk?
ICARE Social Media Post August 2024
BRCA1/2 carriers: Melanoma Risk?
A new study in which ICARE participants were included reported that compared to 1.5% in the general population, the risk of melanoma may be slightly elevated: in BRCA1/2 carriers:○ BRCA1: 2.5%○ BRCA2: 2.3% Read the full article to learn more at: https://tinyurl.com/ye2xxfru Reference: Narod et al. Hered Cancer Clin Pract. 2024;22(1):7. PMID: 38741145.
Permanent link to this article: https://inheritedcancer.net/post82624/
ICARE Social Media Post August 2024
Peritoneal Cancer After Oophorectomy in BRCA1/2 Carriers
ICARE Social Media Post August 2024
Peritoneal Cancer After Oophorectomy in BRCA1/2 Carriers
A recent study among BRCA1 and BRCA2 carriers, which included ICARE participants, found that the risk for peritoneal cancer following a preventive bilateral oophorectomy was higher among BRCA1 carriers than BRCA2 carriers. Specifically, among 6310 women, the annual risk of peritoneal cancer was 0.14% for BRCA1 carriers and 0.06% for BRCA2 carriers, and the 20-year …
Permanent link to this article: https://inheritedcancer.net/post82524/
ICARE Social Media Post August 2024
How to Access NCCN Guidelines
ICARE Social Media Post August 2024
How to Access NCCN Guidelines
Unlock valuable resources for your health journey! 🌟 The National Comprehensive Cancer Network (NCCN) guides clinical practice by providing free access to their guidelines that are available to both patients and healthcare providers. To access the most recent version of cancer-related guidelines that are updated at least annually, create a free username and password at …
Permanent link to this article: https://inheritedcancer.net/post82024/
Permanent link to this article: https://inheritedcancer.net/post80824/
ICARE Social Media Post August 2024
Comparing Cancer Risk Management between Females with Truncating CHEK2 1100delC versus Missense CHEK2 I157T Variants
ICARE Social Media Post August 2024
Comparing Cancer Risk Management between Females with Truncating CHEK2 1100delC versus Missense CHEK2 I157T Variants
In a recent study based on ICARE participants, we compared cancer risk management between those with CHEK2 1100delC (which leads to moderate breast cancer risk, generally more than 20% lifetime risk) versus I157T (which is a low penetrance mutation, with breast cancer risks of less than 20%) 👩🔬 Of the 150 CHEK2 carriers, there were …
Permanent link to this article: https://inheritedcancer.net/post80524/
ICARE Social Media Post July 2024
Genetics Role in Identifying Lower Breast Cancer Risk
ICARE Social Media Post July 2024
Genetics Role in Identifying Lower Breast Cancer Risk
A new study of 25,591 women found: Based on genetic risk, identifying individuals at: This study challenges a one-size-fits all mammogram screening approach. This approach could possibly reduce rising healthcare costs by reallocating resources and lower unnecessary anxiety that comes with frequent screenings, and even prevent unnecessary procedures. Read the full article to learn more …
Permanent link to this article: https://inheritedcancer.net/post72924/
ICARE Social Media Post July 2024
New Study in POT1 Carriers
ICARE Social Media Post July 2024
New Study in POT1 Carriers
In recognition of Sarcoma Awareness Month, a new study found that POT1 mutations are associated with an increased risk for melanoma and a wider variety of different sarcomas than previously described. Specifically, the study showed significant raised risks of around 7-fold for both sarcoma and melanoma. This included many different types of sarcomas, including: Learn …
Permanent link to this article: https://inheritedcancer.net/post72824/
ICARE Social Media Post July 2024
New Genes Raise Breast Cancer Risks Identified in Study of African Women
ICARE Social Media Post July 2024
New Genes Raise Breast Cancer Risks Identified in Study of African Women
A new study, which included ICARE-related efforts through including BEST study participants:▪️ Identified 12 breast cancer genes that may help to predict breast cancer risk▪️ Included more than 40,000 women of African ancestry, almost half of which had breast cancer Why is studying individuals from diverse ancestral backgrounds important?▪️ Refine risks across diverse populations▪️ A …
Permanent link to this article: https://inheritedcancer.net/post72524/
ICARE Social Media Post June 2024
Breast Cancer Patients with BRCA Variants Diagnosed Within 10 Years Postpartum at Higher Mortality Risk
ICARE Social Media Post June 2024
Breast Cancer Patients with BRCA Variants Diagnosed Within 10 Years Postpartum at Higher Mortality Risk
A new study reported that among BRCA carriers, breast cancer diagnosed within 10 years of having a child was associated with a higher risk of mortality, especially in BRCA1 carriers. This information could be important for genetic counseling, prevention, and treatment strategies in BRCA carriers. Learn more by reading the full article at: https://bit.ly/3wHyAIz Reference: …
Permanent link to this article: https://inheritedcancer.net/post60624/
ICARE Social Media Post June 2024
Pregnancy after Breast Cancer: BRCA carriers
ICARE Social Media Post June 2024
Pregnancy after Breast Cancer: BRCA carriers
A new study reported that pregnancy after breast cancer was not associated with adverse maternal prognosis or fetal outcomes. These findings suggest that pregnancy after breast cancer is safe for both mother and baby. Read the full article at: https://bit.ly/3wcoa3xReference: Newman, et al. JAMA Surg. 2024. Online ahead of print. PMID: 38536201. Follow us to …
Permanent link to this article: https://inheritedcancer.net/post60324/
ICARE Social Media Post May 2024
New ASCO Guideline: Selection of Germline Testing Panels in Patients With Cancer
ICARE Social Media Post May 2024
New ASCO Guideline: Selection of Germline Testing Panels in Patients With Cancer
The American Society of Clinical Oncology (ASCO) just released new guidelines for the selection of germline genetic testing panels in patients with cancer. Items addressed include ⤸ What elements are most important in the collection of family history?🧬 Details of cancers in first- and second-degree relatives and the patient’s ethnicity. When and how to use …
Permanent link to this article: https://inheritedcancer.net/post52124/
ICARE Social Media Post May 2024
AACR Cancer Disparities Progress Report 2024
ICARE Social Media Post May 2024
AACR Cancer Disparities Progress Report 2024
The American Association for Cancer Research (AACR) just released a Cancer Disparities Progress Report on May 15th, which includes highlights on inherited cancers! On Page 163, this report discusses policies to address disparities in screening and surveillance for hereditary cancer syndromes. It also highlights an electronic support tool, called MyLynch, that can be used to …
Permanent link to this article: https://inheritedcancer.net/post5172024/
ICARE Social Media Post May 2024
CHEK2: Bi-Allelic Mutations
ICARE Social Media Post May 2024
CHEK2: Bi-Allelic Mutations
Do you know the cancer risks for individuals with CHEK2 bi-allelic mutations (i.e., those with TWO CHEK2 mutations)? A new study found that risks may be higher for multiple types of cancer, including breast cancer, in both females and males ⤸▪️ Females more frequently developed 2 or more cancers at younger ages▪️ Males more frequently …
Permanent link to this article: https://inheritedcancer.net/post50324/
ICARE Social Media Post April 2024
YouTube Channel
ICARE Social Media Post April 2024
YouTube Channel
Curious about inherited cancer and the latest breakthroughs? Look no further than the ICARE YouTube channel! 🎥 Join genetics experts as they dive into discussions on important topics like updates to NCCN cancer risk management guidelines and insights into specific inherited cancer genes. 💡 Don’t miss out on some of our top-viewed videos covering management …
Permanent link to this article: https://inheritedcancer.net/post42824/
ICARE Social Media Post March 2024
Risk Management Strategies for Women with BRCA1/2
ICARE Social Media Post March 2024
Risk Management Strategies for Women with BRCA1/2
Two new research studies that 𝗶𝗻𝗰𝗹𝘂𝗱𝗲𝗱 𝗜𝗖𝗔𝗥𝗘 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝗻𝘁𝘀 showed that risk of death is lowered among BRCA1/2 carriers with 1) MRI screening for breast cancer and 2) removal of both ovaries and fallopian tubes. 💡 In the first study, MRI screening greatly lowered the risk of death from breast cancer (hazard ratio of 0.23) with …
Permanent link to this article: https://inheritedcancer.net/post3524/
ICARE Social Media Post February 2024
Risk-reducing mastectomy and breast cancer mortality in women with BRCA1/BRCA2
ICARE Social Media Post February 2024
Risk-reducing mastectomy and breast cancer mortality in women with BRCA1/BRCA2
🔬 Exciting news! A recent study, which included ICARE participants, suggests the life-saving potential of preventive mastectomy for BRCA1 and BRCA2 carriers. 💪 This procedure significantly reduces the risk of developing breast cancer and may even decrease the risk of breast cancer-related mortality. The study found that after preventive mastectomy, the chance of dying from …
Permanent link to this article: https://inheritedcancer.net/post22724/
PARP Inhibitor (Olaparib) in men with BRCA mutations and prostate cancer
A recent study found that Olaparib (Lynparza) improved survival outcomes among men with BRCA1/2 mutations and metastatic castration-resistant prostate cancer, regardless of whether the mutation was germline or somatic. This underscores the potential of targeted therapies in improving outcomes for those with inherited cancer gene mutations. Learn more at: https://ascopubs.org/doi/10.1200/JCO.23.00339 Reference: Mateo, et al. J …
Permanent link to this article: https://inheritedcancer.net/post22024/
ICARE Social Media Post February 2024
Updates to NCCN Guidelines: Genetic/Familial Breast, Ovarian, and Pancreatic Post #1
ICARE Social Media Post February 2024
Updates to NCCN Guidelines: Genetic/Familial Breast, Ovarian, and Pancreatic Post #1
The National Comprehensive Cancer Network (NCCN) just released updated Genetic/Familial Breast, Ovarian, and Pancreatic Cancer guidelines on February 12th, 2024! Updates include adding contralateral breast cancer risks for BRCA1, BRCA2, PALB2, CHEK2, and other genes to the GENE-A (Cancer Risk Management) table 🧬 You can check out the full guidelines by creating a FREE account …
Permanent link to this article: https://inheritedcancer.net/post21324/
ICARE Social Media Post February 2024 Updates to NCCN Guidelines: Genetic/Familial Breast, Ovarian, and Pancreatic Post #2
The National Comprehensive Cancer Network (NCCN) just released updated Genetic/Familial Breast, Ovarian, and Pancreatic Cancer guidelines on February 12th, 2024! Updates include expanded guidance about gynecologic cancers in BRCA1 and BRCA2, including:✓ Reproductive considerations✓ Non-surgical and surgical risk reduction✓ Salpingectomy✓ Hysterectomy considerations✓ HRT after risk-reducing removal of the ovaries You can check out the full …
Permanent link to this article: https://inheritedcancer.net/post21324_2/
ICARE Social Media Post February 2024
Germline EGFR Mutations and Familial Lung Cancer
ICARE Social Media Post February 2024
Germline EGFR Mutations and Familial Lung Cancer
As featured in our Fall 2023 newsletter, inherited T790M EGFR mutations lead to a higher risk of lung cancer and are more common in the Southeast United States due to a ‘founder effect’. A study, in which our fellow Vanderbilt colleagues contributed, among individuals with this inherited cancer gene mutation found that more than half …
Permanent link to this article: https://inheritedcancer.net/post21224/
ICARE Social Media Post January 2024
Hereditary Cancer Genetic Testing Educational Video
ICARE Social Media Post January 2024
Hereditary Cancer Genetic Testing Educational Video
Want to learn more about genetic testing for inherited cancer? We use patient stories to give information about testing, its possible value to individuals and their family, and ways to access resources to learn more about getting tested. Check out the video here: http://tinyurl.com/genetictestingvideo To get free personalized information about hereditary cancer risk and testing, …
Permanent link to this article: https://inheritedcancer.net/post11724/
ICARE Social Media Post January 2023
Colon Adenomas in Lynch Syndrome
ICARE Social Media Post January 2023
Colon Adenomas in Lynch Syndrome
New research reveals that individuals under the age of 50 with Lynch Syndrome often develop small, flat adenomas, particularly in the right (proximal) colon. This finding emphasizes the importance of rigorous screening, with a special focus on the proximal colon, among these young Lynch Syndrome patients 🩺🔍 Learn more at: https://www.dldjournalonline.com/article/S1590-8658(23)00946-5/fulltext Reference: Alric, et al. …
Permanent link to this article: https://inheritedcancer.net/post11024/
Permanent link to this article: https://inheritedcancer.net/post10524/
ICARE Social Media Post January 2023
BRCA/Prostate Cancer/Treatment
ICARE Social Media Post January 2023
BRCA/Prostate Cancer/Treatment
A recent study suggests that Platinum Chemotherapy is as effective as PARP inhibitors for individuals with BRCA-positive metastatic castration-resistant prostate cancer. The study sheds light on treatment options for advanced prostate cancer patients 🩺✨ Learn more at: http://tinyurl.com/3vs2mk8f Reference: Fazekas, et al. Eur Urol Oncol. 2023: S2588-9311(23)00174-8. PMID: 37722977.
Permanent link to this article: https://inheritedcancer.net/post10324/
ICARE Social Media Post December 2023
BRCA1/2 carriers with Risk Reducing Salpingo-oophorectomy
ICARE Social Media Post December 2023
BRCA1/2 carriers with Risk Reducing Salpingo-oophorectomy
A study among BRCA1/2 carriers who underwent a risk-reducing salpingo-oophorectomy (i.e., removal of both ovaries and fallopian tubes) found that the risk of peritoneal cancer increases if serous tubal intraepithelial carcinoma (STIC) is present – specifically, peritoneal cancer risk was 10.5% with STIC versus 0.3% without STIC at 5 years and 27.5% with STIC versus …
Permanent link to this article: https://inheritedcancer.net/post121923/
ICARE Social Media Post December 2023
BRCA1/2: removing both ovaries and tubes to lower risks
ICARE Social Media Post December 2023
BRCA1/2: removing both ovaries and tubes to lower risks
A recent study among nearly 500 BRCA1/2 carriers who underwent breast cancer surgery found that survival was higher in those who chose preventive removal of their ovaries and fallopian tubes (in order to reduce cancer risks) compared to those who did not, particularly in BRCA1 carriers. Learn more at: https://tinyurl.com/5hdx6ytv Reference: Martelli, et al. JAMA …
Permanent link to this article: https://inheritedcancer.net/post121323/
ICARE Social Media Post December 2023
Tamoxifen and Breast Cancer Risk in BRCA Mutations
ICARE Social Media Post December 2023
Tamoxifen and Breast Cancer Risk in BRCA Mutations
In a recent study among female BRCA1/2 carriers, including ICARE participants, researchers explored the impact of using tamoxifen and/or raloxifene on breast cancer risk. 👩🔬 After almost 7 years of follow-up, only 10.9% of those in the tamoxifen/raloxifene group were diagnosed with breast cancer, compared to 14.3% of those in the non-user group. These findings …
Permanent link to this article: https://inheritedcancer.net/post120523/
Permanent link to this article: https://inheritedcancer.net/post111523/
Permanent link to this article: https://inheritedcancer.net/post110923/
Nov 01
ICARE Social Media Post November 2023
Piloting a Spanish-Language Web-Based Tool for Hereditary Cancer Genetic Testing
ICARE Social Media Post November 2023
Piloting a Spanish-Language Web-Based Tool for Hereditary Cancer Genetic Testing
Language barriers should never prevent people from accessing essential information in the field of healthcare. To fill the gap caused by the lack of Spanish-speaking genetic counselors, our team developed a web-based genetic education tool 🧬 A study among 41 Spanish-speaking found that viewing the tool significantly increased knowledge and feeling informed and empowered to …
Permanent link to this article: https://inheritedcancer.net/post110123/
Nov 01
ICARE Social Media Post November 2023
Piloting a Spanish-Language Web-Based Tool for Hereditary Cancer Genetic Testing
ICARE Social Media Post November 2023
Piloting a Spanish-Language Web-Based Tool for Hereditary Cancer Genetic Testing
Las barreras del idioma nunca deberían impedir que las personas accedan a información esencial en el campo de la atención de salud. Para llenar el vacío causado por la falta de asesores genéticos que hablan español, nuestro equipo desarrolló una herramienta de educación genética basada en la web. Un estudio entre 41 hispanohablantes encontró que …
Permanent link to this article: https://inheritedcancer.net/post110123_1/
Permanent link to this article: https://inheritedcancer.net/post102923/
ICARE Social Media Post October 2023
BRCA1/2 Carriers with Risk-Reducing Salpingo-Oophorectomy: Cancer Worry?
ICARE Social Media Post October 2023
BRCA1/2 Carriers with Risk-Reducing Salpingo-Oophorectomy: Cancer Worry?
A study found that the majority of BRCA1/2 carriers who underwent risk-reducing salpingo-oophorectomy have declining cancer worry. However, a subset had concerns – these individuals are important to identify and try to offer additional support to. Use the following link to learn more: https://bit.ly/3qflyig Reference: van Bommel, et al. Support Care Cancer. 2022;30(4):3409-3418. PMID: 34997316.
Permanent link to this article: https://inheritedcancer.net/post102023/
ICARE Social Media Post October 2023
Navigating BRCA1/2 Choices
ICARE Social Media Post October 2023
Navigating BRCA1/2 Choices
A recent randomized controlled trial among 107 BRCA1/2 carriers, which included ICARE participants, evaluated the effectiveness of a behavioral phone intervention delivered by genetic counselors on the uptake of risk-reducing salpingo-oophorectomy. Women who received the intervention had significantly lower decisional conflict and higher knowledge after one year, and at the two year mark, nearly 54% …
Permanent link to this article: https://inheritedcancer.net/post101223/
ICARE Social Media Post October 2023
BRCA2 & Melanoma Risk
ICARE Social Media Post October 2023
BRCA2 & Melanoma Risk
Are BRCA2 carriers at higher risk for developing melanoma? As featured in our Fall 2023 newsletter, at present, we are not sure because results from different studies have been inconsistent. For instance, one study among 173 families with a BRCA2 mutation found a 2.6-fold risk of developing melanoma; however, another study of 139 Dutch families …
Permanent link to this article: https://inheritedcancer.net/post100623/
Permanent link to this article: https://inheritedcancer.net/post100423/
Permanent link to this article: https://inheritedcancer.net/post83032/
ICARE Social Media Post August 2023
Updates to NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic
ICARE Social Media Post August 2023
Updates to NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic
The National Comprehensive Cancer Network (NCCN) just released updated Genetic/Familial Breast, Ovarian, and Pancreatic Cancer guidelines on August 28th, 2023, which included: You can check out the full guidelines by creating a FREE account at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf
Permanent link to this article: https://inheritedcancer.net/post82923/
ICARE Social Media Post August 2023
FDA Approval Post – Approves Niraparib
ICARE Social Media Post August 2023
FDA Approval Post – Approves Niraparib
A critical step forward in cancer care! The FDA has approved the use of niraparib and abiraterone acetate with prednisone in treating patients with BRCA-mutated castration-resistant prostate cancer. The green light comes backed by the robust efficacy data from the MAGNITUDE trial. Read more about the FDA approval at https://tinyurl.com/dzdvtm9m Learn more about the MAGNITUDE …
Permanent link to this article: https://inheritedcancer.net/post82423/
Permanent link to this article: https://inheritedcancer.net/post82223/
Permanent link to this article: https://inheritedcancer.net/post81823/
Permanent link to this article: https://inheritedcancer.net/post81123/
ICARE Social Media Post August 2023
New Article – Cancer Risk Management
ICARE Social Media Post August 2023
New Article – Cancer Risk Management
A recent study, which 𝗶𝗻𝗰𝗹𝘂𝗱𝗲𝗱 𝗜𝗖𝗔𝗥𝗘 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝗻𝘁𝘀, found that getting care according to guidelines depends on: Therefore, we need ways to improve knowledge among healthcare providers and trust in care among patients! Use this link to learn more: https://tinyurl.com/n26m4zys Reference: Dean, et al. Genet Med. 2023;100945. PMID: 37515473.
Permanent link to this article: https://inheritedcancer.net/post80723/
Permanent link to this article: https://inheritedcancer.net/post72623/
ICARE Social Media Post July 2023
Inherited Cancer Genes in Children: BRCA1/2, PALB2, ATM, CHEK2 , Lynch Genes
ICARE Social Media Post July 2023
Inherited Cancer Genes in Children: BRCA1/2, PALB2, ATM, CHEK2 , Lynch Genes
Recent study findings suggest that BRCA1/2, PALB2, ATM, CHEK2, and the Lynch Syndrome genes might confer reduced penetrance cancer risk among children. However, there are no adjustments to management or testing recommendations based on the level of risk (i.e., normally do not test children for conditions that primarily increase the risk of cancer in adulthood). …
Permanent link to this article: https://inheritedcancer.net/post72123/
ICARE Social Media Post July 2023
BRCA1/2 carriers: Risks with Oral Contraceptives Use
ICARE Social Media Post July 2023
BRCA1/2 carriers: Risks with Oral Contraceptives Use
Among female BRCA1 and BRCA2 carriers, a recent study found that oral contraceptive use is associated with an increased risk of breast cancer, but only among users who have been using them for more than five years, while ovarian cancer risk was nearly cut in half. Use the link in bio to learn more! Reference: …
Permanent link to this article: https://inheritedcancer.net/post70623/
ICARE Social Media Post June 2023
Breast Cancer Risk Model: Predicting Risk over 10-year period
ICARE Social Media Post June 2023
Breast Cancer Risk Model: Predicting Risk over 10-year period
A new study found that mammographic features (density, microcalcifications, masses, and left-right breast asymmetries) predicted risks better than traditional lifestyle/familial risk-based risk models over a 10-year period. Use this link to learn more: https://bit.ly/443GDLd Reference: Eriksson et al. J Clin Oncol. 2023;JCO2201564. PMID: 36930854.
Permanent link to this article: https://inheritedcancer.net/post62823/
ICARE Social Media Post June 2023
Li-Fraumeni Syndrome/TP53 mutations
ICARE Social Media Post June 2023
Li-Fraumeni Syndrome/TP53 mutations
A recent study found that, regardless of a prior cancer diagnosis, there was no increased cancer worry after 1 year of full-body MRI surveillance in TP53 carriers. Further research is needed to evaluate these issues further. Use the link in bio to read the full article! Reference: Omran, et al. Cancer. 2023;129(6):946-955. PMID: 36601958.
Permanent link to this article: https://inheritedcancer.net/post62123/
ICARE Social Media Post June 2023
Should Black women be screened earlier?
ICARE Social Media Post June 2023
Should Black women be screened earlier?
A recent study found that Black women had the highest rate of breast cancer deaths in their 40s, compared to White women and women of other races and ethnicities. Use this link to learn more: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2803948?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=041923 Reference: Chen T, et al. JAMA Netw Open. 2023;6(4):e238893. PMID: 37074714.
Permanent link to this article: https://inheritedcancer.net/post62023/
ICARE Social Media Post June 2023
FDA Advisory Committee Recommendation: Olaparib for Prostate Cancer Treatment
ICARE Social Media Post June 2023
FDA Advisory Committee Recommendation: Olaparib for Prostate Cancer Treatment
Olaparib plus abiraterone acetate is recommended as the first line treatment for metastatic castration-resistant prostate cancer, but only in patients whose tumors have BRCA mutations. Although a broad indication for the combination therapy was desired, concerns about the trial design were raised, and the phase III results did not explicitly show that patients without a …
Permanent link to this article: https://inheritedcancer.net/post61623/
Permanent link to this article: https://inheritedcancer.net/post62223/
Permanent link to this article: https://inheritedcancer.net/post60823/
ICARE Social Media Post June 2023
Inherited Gene Mutation in Those with Multiple Primary Cancers
ICARE Social Media Post June 2023
Inherited Gene Mutation in Those with Multiple Primary Cancers
Among patients with multiple primary cancers, the proportion with inherited cancer gene mutations increased with the number of primary cancers:• 2 cancers: 13.1%• 3 cancers: 15.9%• 4+ cancers: 18.0% Many of the double primaries, such as those of the breast, ovary, colorectum, and endometrium, occurred in women who would already be eligible for genetic testing. …
Permanent link to this article: https://inheritedcancer.net/post60723/
Permanent link to this article: https://inheritedcancer.net/post60523-2/
ICARE Social Media Post June 2023
VUS Results: Rates of Reclassification in Inherited Cancer Genes
ICARE Social Media Post June 2023
VUS Results: Rates of Reclassification in Inherited Cancer Genes
In a multicenter study evaluating reclassifications of variant of uncertain significance (VUS) results in breast, ovarian, and colorectal cancer susceptibility genes, it was discovered that of 3261 VUS results, 8.1% were reclassified. Of all the reclassified VUS results, 11.3% resulted in clinically actionable findings, and 4.6% led to changes in clinical management. The reclassification rates …
Permanent link to this article: https://inheritedcancer.net/post60523/
ICARE Social Media Post May 2023
Cancer Care: Transgender and Gender-Diverse Persons
ICARE Social Media Post May 2023
Cancer Care: Transgender and Gender-Diverse Persons
Did you know that transgender and gender-diverse persons face unique challenges that can influence cancer risk and outcomes? For instance, these individuals face barriers to healthcare access and inequities in treatment, with healthcare providers lacking knowledge about the health needs of this population. Solutions are needed to offer the best care for these individuals. Use …
Permanent link to this article: https://inheritedcancer.net/post52223/
ICARE Social Media Post May 2023
Women’s Health Week
ICARE Social Media Post May 2023
Women’s Health Week
In honor of National Women’s Health Week from May 14th to May 20th, we would like to encourage you to speak with your healthcare provider to make sure you are up-to-date on your cancer screenings, such as mammograms and colonoscopies, to help prevent cancer or find it early when it is easier to treat. Spread …
Permanent link to this article: https://inheritedcancer.net/post51523/
ICARE Social Media Post May 2023
ATM breast cancer risks: High Risk c.7271T>G mutation
ICARE Social Media Post May 2023
ATM breast cancer risks: High Risk c.7271T>G mutation
According to a recent study, while there was a reported 2-fold risk for breast cancer overall among ATM carriers, those with the c.7271T>G mutation had the highest risk. Use the link to learn more: https://bit.ly/40bKovj Reference: Hall et al. Cancer Prev Res (Phila). 2021;14(4):433-440. PMID: 33509806.
Permanent link to this article: https://inheritedcancer.net/post51123/
ICARE Social Media Post May 2023
USPSTF New Recommendation: Mammograms Start at Age 40
ICARE Social Media Post May 2023
USPSTF New Recommendation: Mammograms Start at Age 40
Yesterday the United States Preventive Services Task Force (USPSTF) published a new draft recommendation for all cisgender women and those assigned female sex at birth to do mammograms from ages 40 to 74, every two years. This change in recommendation is due to recent troubling trends, including an increase in the number of cancers diagnosed …
Permanent link to this article: https://inheritedcancer.net/post51023/
Permanent link to this article: https://inheritedcancer.net/post50623/
ICARE Social Media Post May 2023
PARP Inhibitors for Metastatic Prostate Cancer: Talazoparib
ICARE Social Media Post May 2023
PARP Inhibitors for Metastatic Prostate Cancer: Talazoparib
A study that compared a PARP inhibitor (talazoparib) to the standard of care (an androgen receptor inhibitor) in metastatic castration-resistant prostate cancer found that it improved progression-free survival regardless of BRCA mutation status. However, the benefit was greatest in males with a BRCA or other DNA repair gene mutation. Read the full article at this …
Permanent link to this article: https://inheritedcancer.net/post50823/
ICARE Social Media Post April 2023
Cancer Risks in Older Females with a BRCA Mutation
ICARE Social Media Post April 2023
Cancer Risks in Older Females with a BRCA Mutation
A recent study among over 2200 females (aged 50-75) with BRCA mutations, including ICARE participants, found 379 diagnosed cancers with breast and ovarian cancer being the most common cancers observed. Overall cancer risks were 49% in BRCA1 carriers and 43% in BRCA2 carriers, and cancer risks dropped to 9% among those who had preventative removal …
Permanent link to this article: https://inheritedcancer.net/post42823/
ICARE Social Media Post April 2023
Prostate Cancer in Black Men: New Genetic Variants to Explain Higher Risks
ICARE Social Media Post April 2023
Prostate Cancer in Black Men: New Genetic Variants to Explain Higher Risks
Researchers identified 9 new genetic variants that may increase the risk of developing prostate cancer. This study highlights the importance of studying diverse populations. Read the full article at this link: https://www.sciencedirect.com/science/article/abs/pii/S0302283823025617 Reference:Chen et al. Eur Urol. 2023;S0302-2838(23)02561-7. PMID: 36872133.
Permanent link to this article: https://inheritedcancer.net/post42223/
Permanent link to this article: https://inheritedcancer.net/post42123/
ICARE Social Media Post April 2023
PARP Inhibitors for Metastatic Prostate Cancer: Niraparib
ICARE Social Media Post April 2023
PARP Inhibitors for Metastatic Prostate Cancer: Niraparib
A study that evaluated a PARP inhibitor (niraparib) in males with metastatic prostate cancer found that those with a BRCA1 or BRCA2 mutation lived longer on average than those who did not have a BRCA mutation. Read the full article at the link: https://pubmed.ncbi.nlm.nih.gov/35131040/Reference:Smith et al. Lancet Oncol. 2022;23(3):362-373. PMID: 35131040.
Permanent link to this article: https://inheritedcancer.net/post42023/
ICARE Social Media Post April 2023
Applying the Framework for Interventions to Increase Family Communication
ICARE Social Media Post April 2023
Applying the Framework for Interventions to Increase Family Communication
A new study 𝗯𝘆 𝗼𝘂𝗿 𝘁𝗲𝗮𝗺 used the Framework for Developing and Evaluating Complex Interventions (FDECI) to evaluate an intervention to improve family communication of positive genetic test results for inherited cancer. The first FDECI phases were beneficial for improving the intervention and planning for continual effectiveness and future implementation phases. Use the link in …
Permanent link to this article: https://inheritedcancer.net/post41023/
ICARE Social Media Post March 2023
Treatment for PALB2-associated breast cancer with Talazoparib
ICARE Social Media Post March 2023
Treatment for PALB2-associated breast cancer with Talazoparib
According to a recent Phase II study, Talazoparib may benefit patients with PALB2-associated breast cancer. Findings showed that Talazoparib appeared effective and safe in certain patients with advanced disease. Read the full article at this link: https://www.nature.com/articles/s43018-022-00439-1 Reference: Gruber et al. Nat Cancer. 2022;3(10):1181-1191. PMID: 36253484.
Permanent link to this article: https://inheritedcancer.net/post32723/
ICARE Social Media Post March 2023
New Model: To identify those at high risk for Endometrial (Uterine) Cancer
ICARE Social Media Post March 2023
New Model: To identify those at high risk for Endometrial (Uterine) Cancer
Did you know endometrial cancer is the 4th most common cancer among females? Currently, clinical practice guidelines do not recommend endometrial cancer screening in the general population. A new risk prediction model was recently developed to identify those at high risk for endometrial (uterine) cancer to determine who could benefit from cancer screenings and risk-reducing …
Permanent link to this article: https://inheritedcancer.net/post32623/
ICARE Social Media Post March 2023
Inherited Cancer Testing: Pheochromocytoma & Paraganglioma
ICARE Social Media Post March 2023
Inherited Cancer Testing: Pheochromocytoma & Paraganglioma
Because of the high frequency of mutations found in individuals with pheochromocytoma and paraganglioma, these individuals are advised to consider genetic testing for inherited cancer.Use this link to learn more: https://pubmed.ncbi.nlm.nih.gov/35976622/ Reference: Yip, et al. JAMA Surg. 2022;157 (10):870-877. PMID: 35976622
Permanent link to this article: https://inheritedcancer.net/post32223/
ICARE Social Media Post March 2023
Metachronous Colorectal Cancer in Lynch Syndrome
ICARE Social Media Post March 2023
Metachronous Colorectal Cancer in Lynch Syndrome
Findings from a recent study: Risk factors for metachronous colorectal cancer included a history of colorectal polyps and having an MLH1 or MSH2 mutation, while protective factors included female sex and extended surgical resection. This highlights the importance of genetic testing and counseling for Lynch syndrome prior to surgery, which can influence surgical strategy and …
Permanent link to this article: https://inheritedcancer.net/post31923/
ICARE Social Media Post March 2023
Colorectal Cancer Risks: Lynch Syndrome
ICARE Social Media Post March 2023
Colorectal Cancer Risks: Lynch Syndrome
A study on colorectal cancer risks in Lynch Syndrome patients found that:• Colorectal cancer risks were lower in MSH6 and PMS2 carriers• Colonoscopy intervals for these individuals could be longer• Incomplete polyp removal may be responsible for 1/3 of surveillance-detected colorectal cancers Read the full article with the link in bio! Reference: Lamba, et al. …
Permanent link to this article: https://inheritedcancer.net/post31323/
ICARE Social Media Post March 2023
New gene alert: MBD4
ICARE Social Media Post March 2023
New gene alert: MBD4
A new study shows germline MBD4 mutations cause an autosomal recessive tumor predisposing syndrome associated with: This highlights the importance of including MBD4 in genetic testing for polyposis and multi-tumor phenotypes to improve disease management. Use the link in bio to learn more! Reference: Palles, et al. Am J Hum Genet. 2022;109(5):953-960. PMID: 35460607.
Permanent link to this article: https://inheritedcancer.net/post31223/
ICARE Social Media Post March 2023
BGREAT December 2022 Newsletter
ICARE Social Media Post March 2023
BGREAT December 2022 Newsletter
Check out the latest edition of our B-GREAT newsletter for updates about inherited cancers in the context of racial inequalities in healthcare. You can read the newsletter by visiting 👇https://bgreatinitiative.inheritedcancer.net/wp-content/uploads/BGREAT-December-2022-Newsletter.pdf Please feel free to share with family members, friends, and/or your healthcare providers.
Permanent link to this article: https://inheritedcancer.net/post30623/
ICARE Social Media Post March 2023
Melanoma in TP53 /Li-Fraumeni Syndrome
ICARE Social Media Post March 2023
Melanoma in TP53 /Li-Fraumeni Syndrome
A new study found a 7-fold increased incidence of melanoma in individuals with TP53/Li-Fraumeni Syndrome compared with the general population:• Average age was 42• Risk to age 40 was 2.8%• Risk to age 60 was 7.8%• Risk to age 70 was 14.9% Learn more at the link below!https://pubmed.ncbi.nlm.nih.gov/35183552/ Reference: Hatton, et al. J Invest Dermatol. …
Permanent link to this article: https://inheritedcancer.net/post30723/
Permanent link to this article: https://inheritedcancer.net/post22423/
ICARE Social Media Post February 2023
ATM Gene and Breast Cancer Risk for: c.7570G>C Mutation
ICARE Social Media Post February 2023
ATM Gene and Breast Cancer Risk for: c.7570G>C Mutation
While ATM mutations are generally associated with a 25-30% lifetime risk for breast cancer, emerging information suggests that the risk in those with a c.7570G>C mutation may be higher. Once confirmed, this information may be important to guide cancer screening and risk-reducing surgery decisions. Use this link to learn more: https://onlinelibrary.wiley.com/doi/10.1002/ijc.34305
Permanent link to this article: https://inheritedcancer.net/post40623/
Permanent link to this article: https://inheritedcancer.net/post40123/
ICARE Social Media Post January 2023
Inherited Breast Cancers Across Populations
ICARE Social Media Post January 2023
Inherited Breast Cancers Across Populations
Did you know that BRCA1/2 are amongst the most well-studied genes, yet most BRCA1/2 studies have been done in White populations? This means our knowledge about genes and risks comes primarily from White populations. • Some research suggests that BRCA1/2 gene mutations may be more common in young Black women with breast cancer. • Even …
Permanent link to this article: https://inheritedcancer.net/post12423-2/
ICARE Social Media Post January 2023
Updates to NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic
ICARE Social Media Post January 2023
Updates to NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic
The National Comprehensive Cancer Network (NCCN) just released updated breast, ovarian, and pancreatic cancer guidelines which included updated breast cancer screening recommendations for male BRCA carriers (particularly male BRCA2 carriers). It is now recommended that male BRCA carriers consider annual mammograms starting at age 50 or 10 years before the earliest male breast cancer in …
Permanent link to this article: https://inheritedcancer.net/post12423/
ICARE Social Media Post January 2023
New Contralateral Breast Cancer Risk Prediction Model for BRCA1/2 Carriers
ICARE Social Media Post January 2023
New Contralateral Breast Cancer Risk Prediction Model for BRCA1/2 Carriers
A new risk prediction model was developed to assess the risk of contralateral breast cancer in BRCA1/2 carriers. Risks are higher with:• Younger age at first breast cancer• Close family member with breast and/or ovarian cancer• Mutation located near the 3′ region of the gene Risks are lower with:• Endocrine therapy Use this link in …
Permanent link to this article: https://inheritedcancer.net/post11423/
ICARE Social Media Post January 2023
Why is diversity in genomics studies important?
ICARE Social Media Post January 2023
Why is diversity in genomics studies important?
Did you know that about 80% of genomics data comes from European populations, yet they only make up about 16% of the world population? This bias means Europeans stand to benefit the most, while important associations for other ancestry groups may be missed. Not including diverse populations in genomics research can further WIDEN disparities!
Permanent link to this article: https://inheritedcancer.net/post10823/
ICARE Social Media Post December 2022
Negative or Uninformative Test Results
ICARE Social Media Post December 2022
Negative or Uninformative Test Results
A new study demonstrates the importance of retesting patients with previously uninformative cancer genetics evaluations, especially in high risk individuals. Read the full article at this link for more info: https://pubmed.ncbi.nlm.nih.gov/34545504/ 🔗 Reference: Dettwyler et al. Fam Cancer. 2022; DOI: 10.1007/s10689-021-00276-8. PMID: 34545504
Permanent link to this article: https://inheritedcancer.net/post121322/
ICARE Social Media Post December 2022
Bilateral Mastectomy in BRCA1/2, PALB2, ATM, & CHEK2 Carriers
ICARE Social Media Post December 2022
Bilateral Mastectomy in BRCA1/2, PALB2, ATM, & CHEK2 Carriers
A recent study including data from ICARE participants found similar rates of bilateral mastectomy across high (BRCA1, BRCA2, PALB2) and moderate (ATM, CHEK2) penetrance genes. The high rates of bilateral mastectomies seen in those with moderate penetrance genes is concerning for overtreatment. Use the link to learn more: https://jamanetwork.com/journals/jamaoncology/fullarticle/2797978?guestAccessKey=fe9a3a20-8623-4feb-a0c5-315ad43a8fcb&utm_source=jps&utm_medium=email&utm_campaign=author_alert-jamanetwork&utm_content=author-author_engagement&utm_term=1m Reference: Reid et al. Receipt of …
Permanent link to this article: https://inheritedcancer.net/post120822/
Permanent link to this article: https://inheritedcancer.net/post120622/
Permanent link to this article: https://inheritedcancer.net/post112122-2/
ICARE Social Media Post November 2022
Fall 2022 Ask the Expert
ICARE Social Media Post November 2022
Fall 2022 Ask the Expert
In every ICARE newsletter we give our participants the opportunity to have a question addressed by an expert in the field. In the latest edition, Dr. Kamran Idrees, Chief of the Division of Surgical Oncology & Endocrine Surgery, Associate Professor of Surgery, Ingram Associate Professor of Cancer Research, and Director of Pancreatic and Gastro-Intestinal Surgical …
Permanent link to this article: https://inheritedcancer.net/post111122/
ICARE Social Media Post November 2022
Guidelines for Hereditary Breast Cancer Treatment
ICARE Social Media Post November 2022
Guidelines for Hereditary Breast Cancer Treatment
The Expert Panel Consensus, chaired by the Society of Surgical Oncology with the American Society of Clinical Oncology and the American Society of Radiation Oncology, published new recommendations for hereditary breast cancer treatment. Learn more at https://pubmed.ncbi.nlm.nih.gov/32898012/ Reference: Corso & Magnoni. Eur J Cancer Prev. 2021;30(4):311-314. PMID: 32898012.
Permanent link to this article: https://inheritedcancer.net/post110822/
ICARE Social Media Post November 2022
ICARE Fall 2022 Newsletter
ICARE Social Media Post November 2022
ICARE Fall 2022 Newsletter
The ICARE Fall 2022 Newsletter is now available! Check out this latest edition for recent research and clinical updates, a Q&A with Dr. Kamran Idrees from Vanderbilt-Ingram Cancer Center, and an inspiring community spotlight piece. You can read and download a copy of the newsletter at: https://inheritedcancer.net/newsletters/ Please feel free to share with family members, …
Permanent link to this article: https://inheritedcancer.net/post110422/
ICARE Social Media Post October 2022
Tool for Inherited Cancer Predisposition Counseling and Testing Study (TIPS)
ICARE Social Media Post October 2022
Tool for Inherited Cancer Predisposition Counseling and Testing Study (TIPS)
Have you already had genetic testing for inherited cancer and want to get more education and information about what your results mean for you? We provide free education about inherited cancer risk through our Tool for Inherited Cancer Predisposition Counseling and Testing Study (TIPS). Visit https://redcap.link/TIPS and complete our survey. Once completed, we provide:• an …
Permanent link to this article: https://inheritedcancer.net/post102422/
Permanent link to this article: https://inheritedcancer.net/post102122/
Permanent link to this article: https://inheritedcancer.net/post101322/
ICARE Social Media Post October 2022
NCCN Familial/Genetic High Risk Assessment: Breast, Ovarian & Pancreatic Guidelines single post 3
ICARE Social Media Post October 2022
NCCN Familial/Genetic High Risk Assessment: Breast, Ovarian & Pancreatic Guidelines single post 3
On September 7th, 2022, the National Comprehensive Cancer Network (NCCN) released new breast, ovarian, and pancreatic cancer guidelines. In these new guidelines, genetic testing eligibility based on age at breast cancer diagnosis in females was updated from ≤ 45 to ≤ 50 making more females with breast cancer eligible for testing regardless of family history …
Permanent link to this article: https://inheritedcancer.net/post101022/
ICARE Social Media Post October 2022
CanRisk Tool
ICARE Social Media Post October 2022
CanRisk Tool
Have you heard of the CanRisk Tool?The CanRisk Tool provides health care professionals a user-friendly resource to carry out breast and ovarian cancer risk predictions. It is the first freely accessible cancer risk prediction program!Read the full article at the link: https://pubmed.ncbi.nlm.nih.gov/33335023/ Reference: Carver et al. Cancer Epidemiol Biomarkers Prev. 2021 Mar;30(3):469-473. PMID: 33335023.
Permanent link to this article: https://inheritedcancer.net/post100722-2/
ICARE Social Media Post October 2022
NCCN Familial/Genetic High Risk Assessment: Breast, Ovarian & Pancreatic Guidelines – single post 2
ICARE Social Media Post October 2022
NCCN Familial/Genetic High Risk Assessment: Breast, Ovarian & Pancreatic Guidelines – single post 2
On September 7th, 2022, the National Comprehensive Cancer Network (NCCN) released new breast, ovarian, and pancreatic cancer guidelines. In these new guidelines, the age to start breast MRI screening in female ATM and CHEK2 carriers was updated from age 40 to 30-35 making more females eligible for screening at an earlier age.Check out the new …
Permanent link to this article: https://inheritedcancer.net/post100222/
ICARE Social Media Post October 2022
Ovarian Cancer Risks: Weight Gain in BRCA1/2 Carriers
ICARE Social Media Post October 2022
Ovarian Cancer Risks: Weight Gain in BRCA1/2 Carriers
A study found that adult weight gain is a risk factor for ovarian cancer. This highlights the importance for BRCA1/2 carriers to maintain a healthy weight throughout adulthood.Read the full article to learn more! https://pubmed.ncbi.nlm.nih.gov/34426412/Reference: Kim et al. Cancer Epidemiol Biomarkers Prev. 2021 Nov;30(11):2038-2043. PMID: 34426412.
Permanent link to this article: https://inheritedcancer.net/post100122/
ICARE Social Media Post September 2022
Breast cancer risks: BRCA1/2 carriers with risk reducing salpingo-oophorectomy (RRSO)
ICARE Social Media Post September 2022
Breast cancer risks: BRCA1/2 carriers with risk reducing salpingo-oophorectomy (RRSO)
Three recent studies found varying results when evaluating breast cancer risk in BRCA1/2 carriers with risk-reducing salpingo-oophorectomy (RRSO). Use these links to learn more: https://pubmed.ncbi.nlm.nih.gov/31948486/ https://pubmed.ncbi.nlm.nih.gov/33630024/ https://pubmed.ncbi.nlm.nih.gov/35216860/
Permanent link to this article: https://inheritedcancer.net/post92722/
ICARE Social Media Post September 2022
Hormonal Replacement Therapy (HRT) in BRCA1 and BRCA2 carriers
ICARE Social Media Post September 2022
Hormonal Replacement Therapy (HRT) in BRCA1 and BRCA2 carriers
A recent study showed hormone replacement therapy (HRT) is reasonable to offer to BRCA1 and BRCA2 carriers who underwent risk-reducing salpingo-oophorectomy (RSSO). Read the full article at this link: https://pubmed.ncbi.nlm.nih.gov/32143914/Reference: Mills, et al. Gynecol Oncol; 2020 Jun;157(3):706-710. PMID: 32143914.
Permanent link to this article: https://inheritedcancer.net/post2922/
ICARE Social Media Post September 2022
Bilateral Oophorectomy: Breast Cancer Risks in BRCA1 Carriers
ICARE Social Media Post September 2022
Bilateral Oophorectomy: Breast Cancer Risks in BRCA1 Carriers
A recent study, including ICARE participants, found preventive removal of the ovaries does not reduce breast cancer risk in BRCA1 carriers. These findings highlight that study bias can influence results.Read the full article at this link: https://pubmed.ncbi.nlm.nih.gov/35477169/Reference: Kotsopoulos et al. Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1351-1358. PMID: 35477169.
Permanent link to this article: https://inheritedcancer.net/icare-social-media-post-september-2022-bilateral-oophorectomy-breast-cancer-risks-in-brca1-carriers/
ICARE Social Media Post September 2022
NCCN Familial/Genetic High Risk Assessment: Breast, Ovarian & Pancreatic Guidelines – single post 1
ICARE Social Media Post September 2022
NCCN Familial/Genetic High Risk Assessment: Breast, Ovarian & Pancreatic Guidelines – single post 1
On September 7th, 2022, the National Comprehensive Cancer Network (NCCN) released new breast, ovarian, and pancreatic cancer guidelines. In this new version, a table was added at the end of the guidelines to summarize inherited cancer content across 𝗮𝗹𝗹 NCCN guidelines, including live links to the guidelines and sections referenced (see page 54 on the …
Permanent link to this article: https://inheritedcancer.net/post92222/
Permanent link to this article: https://inheritedcancer.net/post92122/
ICARE Social Media Post September 2022
ATM: Breast Cancer Risks
ICARE Social Media Post September 2022
ATM: Breast Cancer Risks
A recent study found that even though ATM has been clearly identified as a breast cancer risk gene with an estimated risk of 13% up to age 80, variant-specific penetrance estimates are needed to guide risk management plans for those with pathogenic mutations.Read the full article at the link: https://pubmed.ncbi.nlm.nih.gov/35365198/Reference: Renault et al. Breast Cancer …
Permanent link to this article: https://inheritedcancer.net/post91922/
Permanent link to this article: https://inheritedcancer.net/post91222/
ICARE Social Media Post September 2022
September ICARE Genetics Case Conference
ICARE Social Media Post September 2022
September ICARE Genetics Case Conference
We are excited to announce that our next ICARE genetics case conference, focused on TERT mutations in myeloid malignancies, will be broadly accessible. We are honored to have Mary Armanios, MD as our guest expert for this conference, in which she will provide a featured presentation and case commentary. We encourage you to join us …
Permanent link to this article: https://inheritedcancer.net/post90822/
ICARE Social Media Post August 2022
Nipple sparing mastectomy: BRCA1/2 carriers
ICARE Social Media Post August 2022
Nipple sparing mastectomy: BRCA1/2 carriers
According to a recent study, a bilateral prophylactic nipple-sparing mastectomy appears to be at least equally as safe as other types of mastectomy for preventing breast cancer. Read the full article at the link: https://pubmed.ncbi.nlm.nih.gov/34342702/Reference: Stanek et al. Aesthetic Plast Surg. 2022 Apr;46(2):706-711. PMID: 34342702.
Permanent link to this article: https://inheritedcancer.net/post82922/
ICARE Social Media Post August 2022
ATM: Breast Cancer Risks
ICARE Social Media Post August 2022
ATM: Breast Cancer Risks
ATM variants are linked to an increased risk of breast cancer, with the ATM V2424G variant causing the highest risks and ATM D1853V, L546V, and S707P variants being the least predictive.Read the full article here: https://pubmed.ncbi.nlm.nih.gov/33402103/Reference: Moslemi, et al. BMC Cancer. 2021 Jan 5;21(1):27. PMID: 33402103.
Permanent link to this article: https://inheritedcancer.net/post81922/
Permanent link to this article: https://inheritedcancer.net/post81222/
ICARE Social Media Post August 2022
Pancreatic Cancer Treatment
ICARE Social Media Post August 2022
Pancreatic Cancer Treatment
A new study reports that maintenance treatment with Olaparib may benefit BRCA1/2 carriers with pancreatic cancer. These findings demonstrated:long-term survival was more commontime to subsequent therapy was prolongedRead the full article at the link: https://ascopubs.org/doi/pdf/10.1200/JCO.21.01604Reference: Kindler et al. J Clin Oncol. 2022; JCO2101604. PMID: 35834777.
Permanent link to this article: https://inheritedcancer.net/post80522/
ICARE Social Media Post July 2022
Pancreatic Cancer Screening
ICARE Social Media Post July 2022
Pancreatic Cancer Screening
A recent study found that earlier diagnosis improved survival in people at high risk of pancreatic cancer.High risk was defined based on:family history and/orinherited gene mutation (BRCA1, BRCA2, CDKN2A, Lynch Syndrome genes, PALB2, ATM, and STK11)Read the article at the link: https://ascopost.com/news/june-2022/outcomes-of-pancreas-surveillance-in-the-caps5-study-and-total-caps-cohort/Reference: Dbouk, et al. J Clin Oncol. 2022 Jun 15:JCO2200298. doi: 10.1200/JCO.22.00298. PMID: 35704792.
Permanent link to this article: https://inheritedcancer.net/post72622/
ICARE Social Media Post June 2022
ATM: High and Moderate Risks for Multiple Cancers
ICARE Social Media Post June 2022
ATM: High and Moderate Risks for Multiple Cancers
A recent study found that pathogenic variants in the Ataxia Telangiectasia Mutated (ATM) gene are associated with multiple cancers. Specifically, moderate-to-high risks for pancreatic, prostate, gastric, and invasive ductal breast cancers, and low-to-moderate risks for ductal carcinoma in situ, male breast cancer, ovarian cancer, colorectal cancer, and melanoma.This provides more data to guide risks and …
Permanent link to this article: https://inheritedcancer.net/post62122/
ICARE Social Media Post June 2022
Refractory Pancreatic or Biliary Cancer
ICARE Social Media Post June 2022
Refractory Pancreatic or Biliary Cancer
A recent small study suggests that immunotherapy may be beneficial for patients with refractory pancreatic or biliary cancer who have inherited homologous recombination deficiency (HRD) genes, BRCA1, BRCA2, and RAD51C.Check out the full article to learn more at 👇https://jamanetwork.com/journals/jamaoncology/article-abstract/2791557Reference: Terrero et al. JAMA Oncol. 2022 Apr:e220611. doi:10.1001/jamaoncol.2022.0611. PMID: 35446342.
Permanent link to this article: https://inheritedcancer.net/post61322/
ICARE Social Media Post June 2022
Maternal Malignancies May Be Identified Through Noninvasive Prenatal Test Results
ICARE Social Media Post June 2022
Maternal Malignancies May Be Identified Through Noninvasive Prenatal Test Results
A new study found that results of noninvasive prenatal testing for fetal aneuploidy screening using cell-free DNA derived from maternal plasma raised suspicion of maternal malignancy in a small proportion of pregnant women. However, among those with suspicious findings, the risk of a confirmed malignancy was quite high.Check out the full article athttps://ascopubs.org/doi/full/10.1200/JCO.21.02260Reference: Heesterbeek et …
Permanent link to this article: https://inheritedcancer.net/post60822/
ICARE Social Media Post June 2022
New Variants Linked to Hereditary Cancer
ICARE Social Media Post June 2022
New Variants Linked to Hereditary Cancer
A new study evaluated 23 hereditary cancer genes and found 19 new gene associations, including 7 new associations with cancer and 12 new associations with non-neoplastic diseases. Specifically, the below genes were found to have an increased risk of disease:APC: benign liver/bile duct tumors, gastritis, and duodenitisATM: stomach cancer and pancreatic cancerBRCA1/2: ovarian cystsCHEK2: leukemia …
Permanent link to this article: https://inheritedcancer.net/post60122/
ICARE Social Media Post May 2022
BRCA Carriers with Risk-Reducing Salpingo-oophorectomy: Risk of Peritoneal Carcinomatosis
ICARE Social Media Post May 2022
BRCA Carriers with Risk-Reducing Salpingo-oophorectomy: Risk of Peritoneal Carcinomatosis
A new study found that among BRCA1/2 carriers, the presence of tubal intraepithelial carcinoma during risk-reducing salpingo-oophorectomy (i.e., preventive surgery to remove the ovaries and fallopian tubes) predicts the risk of later peritoneal cancer. These findings demonstrate:the importance of timely risk-reducing removal of the ovaries and fallopian tubesthat it is VERY important to have a …
Permanent link to this article: https://inheritedcancer.net/post52422/
ICARE Social Media Post May 2022
Breast Cancer Genes in Women of African Ancestry
ICARE Social Media Post May 2022
Breast Cancer Genes in Women of African Ancestry
A recent study in women of African ancestry confirmed genes previously identified to have associations with breast cancer risk (BRCA1, BRCA2, PALB2, ATM, TP53, NF1, and CHEK2) and provided new evidence of breast cancer risk for RAD51C and RAD51D, which was identified previously in European ancestry populations.Check out the full article at 👇https://pubmed.ncbi.nlm.nih.gov/35396981/Reference: Díaz-Zabala, et …
Permanent link to this article: https://inheritedcancer.net/post51722/
Permanent link to this article: https://inheritedcancer.net/post51022/
Permanent link to this article: https://inheritedcancer.net/post50622/
ICARE Social Media Post April 2022
Spring 2022 Ask the Expert
ICARE Social Media Post April 2022
Spring 2022 Ask the Expert
In every ICARE newsletter we give our participants the opportunity to have a question addressed by an expert in the field. In the latest edition, ICARE Founder, Dr. Tuya Pal, and her oncology colleague, Dr. Sonya Reid, discuss the types of inherited breast cancer and whether having an inherited form of breast cancer affects survival.Check …
Permanent link to this article: https://inheritedcancer.net/post42922/
ICARE Social Media Post April 2022
Disparities: PARP Inhibitors & Ovarian Cancer
ICARE Social Media Post April 2022
Disparities: PARP Inhibitors & Ovarian Cancer
A recent study found that non-Hispanic Black and Hispanic women are underrepresented in clinical trials evaluating PARP inhibitor use among ovarian cancer patients; therefore, these trials do not accurately represent the ovarian cancer patient population. These findings indicate initiatives to increase diversity in clinical trials are needed. Read the full article for more information 👇https://www.gynecologiconcology-online.net/article/S0090-8258(22)00071-3/fulltext#secst0030Reference: …
Permanent link to this article: https://inheritedcancer.net/post42222/
ICARE Social Media Post April 2022
BRCA1/2 Carriers with Breast Cancer: Olaparib & Survival
ICARE Social Media Post April 2022
BRCA1/2 Carriers with Breast Cancer: Olaparib & Survival
A new study found that adjuvant olaparib significantly extended survival in BRCA1/2 carriers with HER2-negative high-risk early-stage breast cancer. Learn more at the following link: https://www.healio.com/news/hematology-oncology/20220323/adjuvant-olaparib-prolongs-survival-for-certain-patients-with-early-breast-cancer
Permanent link to this article: https://inheritedcancer.net/post41922/
Permanent link to this article: https://inheritedcancer.net/post40822/
Permanent link to this article: https://inheritedcancer.net/post40522/
ICARE Social Media Post April 2022
Breast Cancer Mortality & MRI Screening: ATM, CHEK2, and PALB2
ICARE Social Media Post April 2022
Breast Cancer Mortality & MRI Screening: ATM, CHEK2, and PALB2
A new study suggests that annual breast MRI screening may reduce deaths from breast cancer by half in women with ATM, CHEK2 and PALB2 gene mutations. The data suggests starting with annual breast MRIs between the ages of 30 to 35, and adding annual mammograms starting at age 40. Read the full article to learn …
Permanent link to this article: https://inheritedcancer.net/post40122/
ICARE Social Media Post March 2022
BRCA1/2: Asian Breast Cancer Patients
ICARE Social Media Post March 2022
BRCA1/2: Asian Breast Cancer Patients
A new study highlights the importance of customizing mutation carrier prediction models in order to improve the accuracy of predicting the likelihood of carrying a BRCA mutation in Asian breast cancer patients.Read the article for more info!https://ascopubs.org/doi/abs/10.1200/JCO.21.01647?cid=DM9826&bid=143994923Reference: Hong Ang et al. J Clin Oncol. 2022 Feb 10;JCO2101647. PMID: 35143328.
Permanent link to this article: https://inheritedcancer.net/post32522/
ICARE Social Media Post March 2022
Breast Cancer: Leading Cause Of Cancer-Associated Death Among Black Women
ICARE Social Media Post March 2022
Breast Cancer: Leading Cause Of Cancer-Associated Death Among Black Women
Did you know breast cancer surpassed lung cancer as the leading cause of cancer death among Black women in the United States? Although Black women are at a lower risk for developing breast cancer, they are 41% more likely to die of breast cancer compared with White women.Future research is needed to reverse course, through …
Permanent link to this article: https://inheritedcancer.net/post31722/
ICARE Social Media Post March 2022
FDA Approves Olaparib for Adjuvant Treatment of High-risk Early Breast Cancer
ICARE Social Media Post March 2022
FDA Approves Olaparib for Adjuvant Treatment of High-risk Early Breast Cancer
On March 11th, the Food and Drug Administration (FDA) approved olaparib (Lynparza) for the adjuvant treatment of BRCA1/2 carriers with human epidermal growth factor receptor 2 (HER2)-negative, high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.Learn more at 👇https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-adjuvant-treatment-high-risk-early-breast-cancer
Permanent link to this article: https://inheritedcancer.net/post31522/
ICARE Social Media Post March 2022
Komen Blog Post: Dr. Pal Interview
ICARE Social Media Post March 2022
Komen Blog Post: Dr. Pal Interview
Komen Scholar, ICARE Founder and Clinical Geneticist, Dr. Tuya Pal, was recently interviewed for the Komen Blog. In the interview, Dr. Pal discusses the importance of making genetic counseling and testing more accessible in order to help populations who are at high risk for inherited cancer make more informed decisions about their medical care.Read the …
Permanent link to this article: https://inheritedcancer.net/post30922/
Permanent link to this article: https://inheritedcancer.net/post30122/
ICARE Social Media Post February 2022
Use of Germline BRCA Testing in Patients With Ovarian Cancer and Commercial Insurance
ICARE Social Media Post February 2022
Use of Germline BRCA Testing in Patients With Ovarian Cancer and Commercial Insurance
A recent study found that only about 33% of women with ovarian cancer undergo germline BRCA1/2 testing, despite universal recommendations for such patients to have germline genetic testing. Check out the article for more information!https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2787937?resultClick=3Reference: Cham et al. JAMA Netw Open. 2022 Jan 4;5(1):e2142703. PMID: 35015069.
Permanent link to this article: https://inheritedcancer.net/post22122/
ICARE Social Media Post Month Year
Genetic Testing & Mortality Among Women with Breast or Ovarian Cancer
ICARE Social Media Post Month Year
Genetic Testing & Mortality Among Women with Breast or Ovarian Cancer
A recent study found there were BETTER short-term outcomes among women with:• triple-negative breast cancer and BRCA1 or BRCA2 mutations• ovarian cancer and BRCA2, BRIP1, RAD51C, or ATM mutationsThese findings may be reassuring to individuals with inherited gene mutations related to breast and ovarian cancer. Read the article to learn more!https://pubmed.ncbi.nlm.nih.gov/34373918/Reference: Kurian et al. J …
Permanent link to this article: https://inheritedcancer.net/post21822/
ICARE Social Media Post February 2022
BRCA1/2 Cancer Risks: Oral Contraceptives
ICARE Social Media Post February 2022
BRCA1/2 Cancer Risks: Oral Contraceptives
A new study found that among BRCA1/2 carriers oral contraceptive use strongly decreases lifetime cancer risk, despite an 𝗶𝗻𝗶𝘁𝗶𝗮𝗹 increase in breast, ovarian, and endometrial cancer risk. Read the full article to learn more!https://pubmed.ncbi.nlm.nih.gov/35048954/Reference: Schrijver et al. J Natl Cancer Inst. 2022 Jan 20;djac004. PMID: 35048954
Permanent link to this article: https://inheritedcancer.net/post21522/
Permanent link to this article: https://inheritedcancer.net/post20822/
Permanent link to this article: https://inheritedcancer.net/post20122/
ICARE Social Media Post January 2022
Male Cancer Risks: BRCA1 & BRCA2
ICARE Social Media Post January 2022
Male Cancer Risks: BRCA1 & BRCA2
A new study found that male BRCA1/2 carriers have a higher risk for breast, pancreatic, and stomach cancer. Additionally, male BRCA2 carriers were found to have higher risks for prostate cancer. Read the full Journal of Clinical Oncology article to learn more!https://ascopubs.org/doi/full/10.1200/JCO.21.02112Reference: Li et al. J Clin Oncol. 2022 Jan 25;JCO2102112. PMID: 35077220.
Permanent link to this article: https://inheritedcancer.net/post12822/
ICARE Social Media Post January 2022
Overview of genetic services delivery for hereditary breast cancer
ICARE Social Media Post January 2022
Overview of genetic services delivery for hereditary breast cancer
A recent article by Drs. Sonya Reid, Tuya Pal, and Lucy Spalluto, and Katie Lang, MS, CGC and Anne Weidner, MPH of the ICARE team, has just been published with @SpringerNature in 𝘉𝘳𝘦𝘢𝘴𝘵 𝘊𝘢𝘯𝘤𝘦𝘳 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘢𝘯𝘥 𝘛𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵. This article outlines the importance of genetic services and follow-up care for hereditary breast cancer, as well as …
Permanent link to this article: https://inheritedcancer.net/post12622/
ICARE Social Media Post January 2022
BRCA Breast Cancer Risks After Age 60
ICARE Social Media Post January 2022
BRCA Breast Cancer Risks After Age 60
A study that included ICARE participants reported the risk of developing breast cancer remains high after age 60 in both BRCA1 and BRCA2 carriers. Read the article to learn more!https://pubmed.ncbi.nlm.nih.gov/33423179/Reference: Stjepanovic et al. Breast Cancer Res Treat. 2021 Jun;187(2):515-523. PMID: 33423179
Permanent link to this article: https://inheritedcancer.net/post12522/
Jan 21
ICARE Social Media Post January 2022
Belzutifan in Von Hippel-Lindau Disease Patients
ICARE Social Media Post January 2022
Belzutifan in Von Hippel-Lindau Disease Patients
Belzutifan demonstrated clinical efficacy in patients with renal cell carcinoma who have Von Hippel-Lindau Disease. Learn more by reading the full The New England Journal of Medicine article at 👇https://www.nejm.org/doi/full/10.1056/NEJMoa2103425Reference: Jonasch, et al. N Engl J Med. 2021 Nov 25;385(22):2036-2046. PMID: 34818478.
Permanent link to this article: https://inheritedcancer.net/post12122/
ICARE Social Media Post January 2022
Dr. Pal’s GIM Editorial
ICARE Social Media Post January 2022
Dr. Pal’s GIM Editorial
Estimating Polygenetic Risk Scores in non-Europeans through extrapolating from data in European descent populations is not accurate! Diversity in genomic studies is critically needed for both equity and scientific discovery. For more information, read the Genetics in Medicine editorial by ICARE Founder, Dr. Tuya Pal, here 👇https://www.gimjournal.org/article/S1098-3600(21)05396-X/fulltextReference: Pal. Genet Med. 2021 Nov 20;S1098-3600(21)05396-X. PMID: 34906472.
Permanent link to this article: https://inheritedcancer.net/post11822/
Permanent link to this article: https://inheritedcancer.net/post11122/
Permanent link to this article: https://inheritedcancer.net/post10422/
ICARE Social Media Post December 2021
Fall 2021 Community Spotlight
ICARE Social Media Post December 2021
Fall 2021 Community Spotlight
In every ICARE newsletter we feature a 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆 𝘀𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁 to share their experience with inherited cancer. In the latest edition, Dan Dry Dock Shockley, shares his experience with attenuated familial adenomatous polyposis (AFAP). Check out his full story at 👇https://inheritedcancer.net/community-spotlight/
Permanent link to this article: https://inheritedcancer.net/post123021/
ICARE Social Media Post December 2021
Fall 2021 Ask the Expert
ICARE Social Media Post December 2021
Fall 2021 Ask the Expert
In every ICARE newsletter we give our participants the opportunity to have a question addressed by an expert in the field. In the latest edition, Dr. Kerry Schaffer discusses the use of PARP inhibitors to treat inherited forms of prostate cancer.Check out Dr. Schaffer’s full response at 👇https://inheritedcancer.net/newsletters/
Permanent link to this article: https://inheritedcancer.net/post122821/
ICARE Social Media Post December 2021
Breast Cancer Risk Prediction Model for Black Women
ICARE Social Media Post December 2021
Breast Cancer Risk Prediction Model for Black Women
A new breast cancer model has been developed and validated for breast cancer risk prediction, specifically for Black women in the United States. This is in contrast to prior models, which were developed in White women, and used in Black women (which UNDERPREDICTED risks). This is a notable advance as we strive towards health equity …
Permanent link to this article: https://inheritedcancer.net/post122321/
ICARE Social Media Post December 2021
Li-Fraumeni Syndrome Cancer Risks
ICARE Social Media Post December 2021
Li-Fraumeni Syndrome Cancer Risks
• Several variants were identified multiple times in those who did and did not meet Li-Fraumeni Syndrome clinical criteria: p.R175, p.G245, p.R248, p.R273, and p.R282• Other variants were exclusively found in those in the Li-Fraumeni Syndrome group: p.M133T, p.P152L, p.C275Y, p.C275, p.R337C, p.R342, and p.R342P• One variant was exclusively found in patients with attenuated Li-Fraumeni …
Permanent link to this article: https://inheritedcancer.net/post122121/
ICARE Social Media Post December 2021
Prostate Cancer Screening: MSH2 & MSH6
ICARE Social Media Post December 2021
Prostate Cancer Screening: MSH2 & MSH6
A new study suggests men with MSH2 and MSH6 mutations have a higher incidence of prostate cancer, and may be candidates for PSA screening. Read the full article to learn more 👇 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00522-2/fulltext Reference: Bancroft et al. Lancet Oncol. 2021 Nov;22(11):1618-1631. PMID: 34678156.
Permanent link to this article: https://inheritedcancer.net/post121721/
ICARE Social Media Post December 2021
FDA Approves Belzutifan for Cancers Associated With von Hippel-Lindau Disease
ICARE Social Media Post December 2021
FDA Approves Belzutifan for Cancers Associated With von Hippel-Lindau Disease
On August 13th, the FDA approved the use of belzutifan (Welireg) for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors not requiring immediate surgery. For more information, check out The ASCO Post article at 👇https://ascopost.com/news/august-2021/fda-approves-belzutifan-for-cancers-associated-with-von-hippel-lindau-disease/?utm_source=TAP-EN-081321&utm_medium=email&utm_term=49cf1c97d48c2cf8231827e3bcb15769
Permanent link to this article: https://inheritedcancer.net/post121021/
ICARE Social Media Post December 2021
FDA Approves PARP Inhibitor (Olaparib) Treatment for some BRCA carriers with Early Stage Breast Cancer
ICARE Social Media Post December 2021
FDA Approves PARP Inhibitor (Olaparib) Treatment for some BRCA carriers with Early Stage Breast Cancer
FDA granted priority review to Olaparib for adjuvant treatment of certain patients with high-risk breast cancer. This designation applies to use of the agent by patients with BRCA-mutated, HER2-negative, high-risk early breast cancer who receive chemotherapy before or after surgery. For additional information, visit: https://tinyurl.com/healioFDAapproval
Permanent link to this article: https://inheritedcancer.net/post120621/
ICARE Social Media Post December 2021
The Impact of Subtype and Race on Breast Cancer Survival
ICARE Social Media Post December 2021
The Impact of Subtype and Race on Breast Cancer Survival
A recent article 𝗹𝗲𝗱 𝗯𝘆 𝗗𝗿𝘀. 𝗦𝗼𝗻𝘆𝗮 𝗥𝗲𝗶𝗱 𝗮𝗻𝗱 𝗧𝘂𝘆𝗮 𝗣𝗮𝗹 𝗼𝗳 𝘁𝗵𝗲 𝗜𝗖𝗔𝗥𝗘 𝘁𝗲𝗮𝗺, published in 𝘉𝘳𝘦𝘢𝘴𝘵 𝘊𝘢𝘯𝘤𝘦𝘳 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘢𝘯𝘥 𝘛𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵, outlines the impact of race and molecular subtype on HR+, HER2- breast cancer survival. Check out the full article at https://link.springer.com/content/pdf/10.1007/s10549-021-06342-0.pdf Reference: Reid et al. Breast Cancer Res Treat. 2021 Oct;189(3):845-852. PMID: 34331630.
Permanent link to this article: https://inheritedcancer.net/post120321/
ICARE Social Media Post November 2021
Variation in Colorectal Cancer Risk in Families With Lynch Syndrome
ICARE Social Media Post November 2021
Variation in Colorectal Cancer Risk in Families With Lynch Syndrome
For more information, read the Lancet Oncology article led by The International Mismatch Repair Consortium at the below link 👇https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00189-3/fulltext Reference: International Mismatch Repair Consortium. Lancet Oncol. 2021 Jul;22(7):1014-1022. PMID: 34111421.
Permanent link to this article: https://inheritedcancer.net/post113021/
Permanent link to this article: https://inheritedcancer.net/post110921/
Permanent link to this article: https://inheritedcancer.net/post110221/
Permanent link to this article: https://inheritedcancer.net/post100121/
ICARE Social Media Post September 2021
USA Today Article: Fighting Cancer with Your Own Family History
ICARE Social Media Post September 2021
USA Today Article: Fighting Cancer with Your Own Family History
Check out the full 𝘜𝘚𝘈 𝘛𝘰𝘥𝘢𝘺 article, featuring commentary from Dr. Tuya Pal (ICARE Founder), highlighting the importance of PALB2 as an inherited breast cancer gene: https://www.futureofpersonalhealth.com/breast-health/fighting-cancer-with-your-own-family-history/# Additional guidance is available through an impactful PALB2 practice resource recently published through ACMG: https://www.acmg.net/PDFLibrary/41436_2021_1151_OnlinePDF.pdf Reference: Tischkowitz, et al. Genet Med. 2021 Aug;23(8):1416-1423. PMID: 33976419
Permanent link to this article: https://inheritedcancer.net/post92221/
ICARE Social Media Post September 2021
New NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Guidelines (Released August 11th)
ICARE Social Media Post September 2021
New NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Guidelines (Released August 11th)
The National Comprehensive Cancer Network (NCCN) released new guidelines on August 11th for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. You can check out the full guidelines by creating a FREE account at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf
Permanent link to this article: https://inheritedcancer.net/post91021/
Permanent link to this article: https://inheritedcancer.net/post83121/
Permanent link to this article: https://inheritedcancer.net/post82421/
Permanent link to this article: https://inheritedcancer.net/post82021/
ICARE Social Media Post August 2021
New York Times PALB2 Article
ICARE Social Media Post August 2021
New York Times PALB2 Article
A New York Times article just published focused on the importance of PALB2 as a breast cancer gene (https://www.nytimes.com/…/breast-cancer-palb2-brca.html), which referenced our recent article focused on managing PALB2 carriers sponsored by ACMG – American College of Medical Genetics and Genomics, and developed through a worldwide collaboration (including: Marc Tischkowicz, Judith Balmana, Will Foulkes, Paul James, …
Permanent link to this article: https://inheritedcancer.net/post81921/
Permanent link to this article: https://inheritedcancer.net/post81621/
Permanent link to this article: https://inheritedcancer.net/post81321/
ICARE Social Media Post August 2021
ASCO Guideline Update: Olaparib for Breast Cancer
ICARE Social Media Post August 2021
ASCO Guideline Update: Olaparib for Breast Cancer
For additional information, read the updated American Society of Clinical Oncology (ASCO) recommendation (released June 15th, 2021) at the following link: https://www.asco.org/practice-patients/guidelines/breast-cancer?intcmp=ws_ascoorg_gdlns_hereditarybreastcancer_site_pressrelease_061621____#/143725
Permanent link to this article: https://inheritedcancer.net/post81021/
Permanent link to this article: https://inheritedcancer.net/post80621/
Permanent link to this article: https://inheritedcancer.net/post80321/
Permanent link to this article: https://inheritedcancer.net/post72721/
Permanent link to this article: https://inheritedcancer.net/post72021/
Permanent link to this article: https://inheritedcancer.net/post71621/
Permanent link to this article: https://inheritedcancer.net/post71321/
Permanent link to this article: https://inheritedcancer.net/post70921/
ICARE Social Media Post July 2021
Advances in Pancreatic Cancer Treatment: PALB2 & BRCA1/2
ICARE Social Media Post July 2021
Advances in Pancreatic Cancer Treatment: PALB2 & BRCA1/2
For more information, view the article at the following link below: https://ascopubs.org/doi/abs/10.1200/JCO.21.00003 You may also read the ASCO post article at: https://ascopost.com/news/may-2021/maintenance-rucaparib-in-patients-with-platinum-sensitive-pancreatic-cancer-and-germline-or-somatic-brca1-brca2-or-palb2-variants/?utm_source=TAP%2DEN%2D051221%2DTrending%5FLymphoma&utm_medium=email&utm_term=49cf1c97d48c2cf8231827e3bcb15769
Permanent link to this article: https://inheritedcancer.net/post70621/
Permanent link to this article: https://inheritedcancer.net/post70221/
Permanent link to this article: https://inheritedcancer.net/post62921/
Permanent link to this article: https://inheritedcancer.net/post62521/
Permanent link to this article: https://inheritedcancer.net/post62221/
Permanent link to this article: https://inheritedcancer.net/post61521/
Permanent link to this article: https://inheritedcancer.net/post61121/
Permanent link to this article: https://inheritedcancer.net/post52821/
ICARE Social Media Post May 2021
Breast Cancer Awareness Medical Minute
ICARE Social Media Post May 2021
Breast Cancer Awareness Medical Minute
In recognition of 𝗪𝗼𝗺𝗲𝗻’𝘀 𝗛𝗲𝗮𝗹𝘁𝗵 𝗠𝗼𝗻𝘁𝗵, listen to our colleague, Dr. Sonya Reid, talk about the importance of mammography for the early detection of breast cancer! To learn more, check out the American Cancer Society’s Recommendations for the Early Detection of Breast Cancer at: https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html
Permanent link to this article: https://inheritedcancer.net/post52421/
ICARE Social Media Post May 2021
USPSTF Earlier Colorectal Cancer Screening At Age 45
ICARE Social Media Post May 2021
USPSTF Earlier Colorectal Cancer Screening At Age 45
The United States Preventive Services Task Force (USPSTF) now recommends routine colorectal cancer screening begin at age 45 (lowered from the previous recommendation to start screening at age 50) due to an increasing number of colorectal cancer cases in younger adults. For more information, check out the full JAMA article at: https://jamanetwork.com/journals/jama/fullarticle/2779985
Permanent link to this article: https://inheritedcancer.net/post52121/
ICARE Social Media Post May 2021
ACMG Gene List
ICARE Social Media Post May 2021
ACMG Gene List
The American College of Medical Genetics and Genomics (ACMG) recently released the highly anticipated recommended minimum gene list for reporting secondary findings (SF) in clinical exome and genome sequencing. ACMG SF v3.0 added 3 new cancer genes (𝘗𝘈𝘓𝘉2, 𝘔𝘈𝘟, and 𝘛𝘔𝘌𝘔127) to bring the total number of inherited cancer genes to 28. For more information …
Permanent link to this article: https://inheritedcancer.net/post52121_2/
Permanent link to this article: https://inheritedcancer.net/post51821/
ICARE Social Media Post May 2021
CDKN2A: Cancer Risks and Risk Management
ICARE Social Media Post May 2021
CDKN2A: Cancer Risks and Risk Management
𝘐𝘯 𝘳𝘦𝘤𝘰𝘨𝘯𝘪𝘵𝘪𝘰𝘯 𝘰𝘧 𝘴𝘬𝘪𝘯 𝘤𝘢𝘯𝘤𝘦𝘳 𝘢𝘸𝘢𝘳𝘦𝘯𝘦𝘴𝘴 𝘮𝘰𝘯𝘵𝘩, we present cancer risks and management for 𝗖𝗗𝗞𝗡𝟮𝗔 per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Version 2.2021 𝗠𝗲𝗻 & 𝗪𝗼𝗺𝗲𝗻:Melanoma risk: Elevated at 28-67% – Recommend annual full-body skin exam, regular self-examinations, and routine sun protective behaviors. Pancreatic cancer risk: >15% – Consider MRI/MRCP and/or endoscopic …
Permanent link to this article: https://inheritedcancer.net/post51321/
ICARE Social Media Post May 2021
ACMG Clinical Practice Resource on PALB2
ICARE Social Media Post May 2021
ACMG Clinical Practice Resource on PALB2
Check out the newly released ACMG Clinical Practice Resource on 𝗣𝗔𝗟𝗕𝟮 developed through a group of worldwide experts!https://www.acmg.net/PDFLibrary/41436_2021_1151_OnlinePDF.pdf Read the ACMG press release at: https://www.acmg.net/PDFLibrary/Global%20Team%20of%20Cancer%20Genetic%20Specialists%20release%20final%20template%205%206.final.pdf
Permanent link to this article: https://inheritedcancer.net/post51121/
Permanent link to this article: https://inheritedcancer.net/post50321/
ICARE Social Media Post April 2021
Reducing Hereditary Cancer Act
ICARE Social Media Post April 2021
Reducing Hereditary Cancer Act
The 𝙍𝙚𝙙𝙪𝙘𝙞𝙣𝙜 𝙃𝙚𝙧𝙚𝙙𝙞𝙩𝙖𝙧𝙮 𝘾𝙖𝙣𝙘𝙚𝙧 𝘼𝙘𝙩 is being proposed to ensure Medicare beneficiaries have access to inherited cancer genetic testing, increased screening, and risk-reducing procedures, when medically necessary & appropriate. Under current Medicare guidelines, only those with “signs, symptoms, complaints, or personal histories of disease” meet the criteria for medical services coverage. Genetic testing is only …
Permanent link to this article: https://inheritedcancer.net/post43021/
Permanent link to this article: https://inheritedcancer.net/post42821/
ICARE Social Media Post April 2021
Addressing Racial Disparities in Breast Cancer Clinical Trial Enrollment
ICARE Social Media Post April 2021
Addressing Racial Disparities in Breast Cancer Clinical Trial Enrollment
For more information, read the recently published ASCO Daily News editorial led by 𝗗𝗿. 𝗦𝗼𝗻𝘆𝗮 𝗥𝗲𝗶𝗱 from Vanderbilt University Medical Center, which focused on racial disparities in breast cancer clinical trial enrollment: https://dailynews.ascopubs.org/do/10.1200/ADN.21.200499/full/
Permanent link to this article: https://inheritedcancer.net/post42321/
ICARE Social Media Post April 2021
Komen Disparities Resource
ICARE Social Media Post April 2021
Komen Disparities Resource
Check out Susan G. Komen’s “𝗞𝗻𝗼𝘄 𝗬𝗼𝘂𝗿 𝗛𝗶𝘀𝘁𝗼𝗿𝘆, 𝗞𝗻𝗼𝘄 𝗬𝗼𝘂𝗿 𝗥𝗶𝘀𝗸” resource, which outlines disparities in breast cancer, how to understand your risk, and recommended screening and management practices. To learn more, please visit: 👉 https://www.komen.org/about-komen/our-impact/breast-cancer/health-equities-initiative/know-your-history/ 👉 https://blog.komen.org/news/black-history-month/
Permanent link to this article: https://inheritedcancer.net/post42021/
Permanent link to this article: https://inheritedcancer.net/post41321/
ICARE Social Media Post April 2021
Winter 2021 Ask the Expert
ICARE Social Media Post April 2021
Winter 2021 Ask the Expert
In every ICARE newsletter we give our participants the opportunity to have a question addressed by an expert in the field. In the latest edition, Dr. Rebecca Smith explains how a genetic change (or mutation) is classified as pathogenic or benign. Check out Dr. Smith’s full response in our Winter 2021 newsletter at: https://inheritedcancer.net/newsletters/
Permanent link to this article: https://inheritedcancer.net/post40921/
Permanent link to this article: https://inheritedcancer.net/post40621/
Permanent link to this article: https://inheritedcancer.net/post40221/
ICARE Social Media Post March 2021
STK11: Cancer Risks and Risk Management
ICARE Social Media Post March 2021
STK11: Cancer Risks and Risk Management
Gene: STK11 Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Version 1.2020 Women:Breast cancer risk: Elevated at 40-60% – Recommend annual mammogram and breast MRI starting at around age 30. Ovarian tumor risk (typically benign sex cord/Sertoli cell tumors): Elevated at 18-21% – Recommend annual pelvic exam starting at …
Permanent link to this article: https://inheritedcancer.net/post33021/
ICARE Social Media Post March 2021
MUTYH: Cancer Risks and Risk Management
ICARE Social Media Post March 2021
MUTYH: Cancer Risks and Risk Management
Gene: MUTYH Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Version 1.2020 Men & women with two mutations in MUTYH:Colon cancer risk: High risk – Recommend colonoscopy every 1-2 years beginning at age 25-30; colectomy considered based on polyp burden and age. Duodenal cancer risk: Elevated – Consider baseline …
Permanent link to this article: https://inheritedcancer.net/post32321/
Permanent link to this article: https://inheritedcancer.net/post31921/
ICARE Social Media Post March 2021
APC: Cancer Risks and Risk Management
ICARE Social Media Post March 2021
APC: Cancer Risks and Risk Management
𝗚𝗲𝗻𝗲: 𝗔𝗣𝗖 Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Version 1.2020 𝗠𝗲𝗻 & 𝗪𝗼𝗺𝗲𝗻:𝘈𝘗𝘊 mutation leading to classic form of Familial Adenomatous Polyposis (FAP):Colorectal cancer risk: >99% if untreated – Treatment is based on polyp burden and includes proctocolectomy (with subsequent endoscopic screening of the ileal pouch) or …
Permanent link to this article: https://inheritedcancer.net/post31621/
ICARE Social Media Post March 2021
Colorectal Cancer Risk Assessment Tool
ICARE Social Media Post March 2021
Colorectal Cancer Risk Assessment Tool
In honor of 𝗖𝗼𝗹𝗼𝗿𝗲𝗰𝘁𝗮𝗹 𝗖𝗮𝗻𝗰𝗲𝗿 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗠𝗼𝗻𝘁𝗵, we wanted to highlight the National Cancer Institute’s Colorectal Cancer Risk Assessment Tool (CCRAT) designed for healthcare providers to use with select patients to estimate the risk of colorectal cancer. You may access the tool at https://ccrisktool.cancer.gov
Permanent link to this article: https://inheritedcancer.net/post31221/
Permanent link to this article: https://inheritedcancer.net/post30921/
Permanent link to this article: https://inheritedcancer.net/post30221/
Permanent link to this article: https://inheritedcancer.net/post22321/
ICARE Social Media Post February 2021
ICARE Winter 2021 Newsletter
ICARE Social Media Post February 2021
ICARE Winter 2021 Newsletter
The ICARE Winter 2021 Newsletter is now available! Check out this latest edition for recent research and clinical updates, a Q&A with a genomics expert, and an inspiring community spotlight piece. You can read the newsletter by visiting: https://inheritedcancer.net/wp-content/uploads/ICARE-2021-Winter-Newsletter.pdf. Please feel free to share with family members, friends, and/or your healthcare providers.
Permanent link to this article: https://inheritedcancer.net/post20921/
ICARE Social Media Post February 2021
Sharing Genetic Test Results with Family Members of BRCA, PALB2, CHEK2, and ATM Carriers
ICARE Social Media Post February 2021
Sharing Genetic Test Results with Family Members of BRCA, PALB2, CHEK2, and ATM Carriers
Our team recently published “Sharing Genetic Test Results with Family Members of 𝘉𝘙𝘊𝘈, 𝘗𝘈𝘓𝘉2, 𝘊𝘏𝘌𝘒2, and 𝘈𝘛𝘔 Carriers” in 𝘗𝘢𝘵𝘪𝘦𝘯𝘵 𝘌𝘥𝘶𝘤𝘢𝘵𝘪𝘰𝘯 𝘢𝘯𝘥 𝘊𝘰𝘶𝘯𝘴𝘦𝘭𝘪𝘯𝘨 Special Issue on Genetics. View the article available at:https://www.sciencedirect.com/science/article/pii/S0738399120306832 Challenges and barriers to family sharing included concern for family members’ reactions, complexities of information, lack of closeness, perceived relevance, & emotional impact. …
Permanent link to this article: https://inheritedcancer.net/post20821/
ICARE Social Media Post February 2021
Strategies to Enhance the Identification of Hereditary Breast Cancer Gene Carriers
ICARE Social Media Post February 2021
Strategies to Enhance the Identification of Hereditary Breast Cancer Gene Carriers
Check out a recent review article led by the ICARE team, published in 𝘌𝘹𝘱𝘦𝘳𝘵 𝘙𝘦𝘷𝘪𝘦𝘸 𝘰𝘧 𝘔𝘰𝘭𝘦𝘤𝘶𝘭𝘢𝘳 𝘋𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤𝘴, outlining strategies to improve the identification of inherited breast cancer gene carriers. Check out the full article at: https://www.tandfonline.com/doi/pdf/10.1080/14737159.2020.1816829?needAccess=true
Permanent link to this article: https://inheritedcancer.net/post20221/
ICARE Social Media Post January 2021
Male Breast Cancer Global Alliance
ICARE Social Media Post January 2021
Male Breast Cancer Global Alliance
The Male Breast Cancer Global Alliance shares stories from male breast cancer survivors all over the world. To learn more and find resources for affected men and their families, please visit www.mbcglobalalliance.org. The Male Breast Cancer Global Alliance also developed printable and shareable cards in over 20 languages outlining the proper way to do self-breast …
Permanent link to this article: https://inheritedcancer.net/post12621/
ICARE Social Media Post January 2021
COVID-19 Vaccine Myths
ICARE Social Media Post January 2021
COVID-19 Vaccine Myths
Although we don’t typically post on vaccines, given the public health importance of the COVID-19 vaccine and the questions we have received related to whether the vaccine could change one’s DNA, we …
Permanent link to this article: https://inheritedcancer.net/post12221/
ICARE Social Media Post January 2021
Sharing Genetic Test Results with Family Members of BRCA, PALB2, CHEK2, and ATM
ICARE Social Media Post January 2021
Sharing Genetic Test Results with Family Members of BRCA, PALB2, CHEK2, and ATM
Check out a new article by the ICARE team, published in Patient Education and Counseling, evaluating the motivators and barriers to sharing personal genetic test results with family members. The article is 𝗳𝗿𝗲𝗲 to access and download 𝘂𝗻𝘁𝗶𝗹 𝗠𝗮𝗿𝗰𝗵 𝟱𝘁𝗵 at: https://www.sciencedirect.com/science/article/pii/S0738399120306832
Permanent link to this article: https://inheritedcancer.net/post11521/
ICARE Social Media Post January 2021
Qualitative Methods for Refining a Web-Based Educational Tool for Patients Focused on Inherited Cancer Predisposition
ICARE Social Media Post January 2021
Qualitative Methods for Refining a Web-Based Educational Tool for Patients Focused on Inherited Cancer Predisposition
Check out a study led by the ICARE team, published with @SpringerNature in the Journal of Cancer Education, outlining the evaluation and refinement strategies of an interactive web-based tool developed to provide education about inherited cancer risk. Check out a full-text view-only version of the paper at https://rdcu.be/cc8sR or read the abstract at https://pubmed.ncbi.nlm.nih.gov/33400205/ (PMID: …
Permanent link to this article: https://inheritedcancer.net/post11221/
ICARE Social Media Post January 2021
Family Sharing Resources: GeneSHARE
ICARE Social Media Post January 2021
Family Sharing Resources: GeneSHARE
With the tremendous advances in gene-based care among those at risk for inherited cancer, we are trying to develop and improve tools and strategies to make it easier for more people to benefit from genetic testing. We are excited to share with you a free online toolkit called 𝗚𝗲𝗻𝗲𝗦𝗛𝗔𝗥𝗘, which is aimed at helping patients …
Permanent link to this article: https://inheritedcancer.net/post10821/
Permanent link to this article: https://inheritedcancer.net/post10521/
ICARE Social Media Post December 2020
Genetic Testing in Women with Breast Cancer
ICARE Social Media Post December 2020
Genetic Testing in Women with Breast Cancer
Approximately 4,000 women with breast cancer were tested for mutations in nine breast cancer genes – 6.2% had mutations in at least one of the nine genes, and 2.7% had mutations in either 𝘽𝙍𝘾𝘼1 or 𝘽𝙍𝘾𝘼2. Comparisons between women who did versus did not meet National Comprehensive Cancer Network (NCCN) guidelines for testing showed that: …
Permanent link to this article: https://inheritedcancer.net/post122920/
Permanent link to this article: https://inheritedcancer.net/post122220/
Permanent link to this article: https://inheritedcancer.net/post121820/
ICARE Social Media Post December 2020
CDH1 Cancer Risks
ICARE Social Media Post December 2020
CDH1 Cancer Risks
When a 𝘾𝘿𝙃1 mutation is identified, several factors should be considered to figure out what the cancer risks might be and what medical management should be advised. Specifically, differences in cancer risks among those with a 𝘾𝘿𝙃1 mutation are not well understood. Identifying a 𝘾𝘿𝙃1 mutation in families with hereditary diffuse gastric cancer (HDGC) …
Permanent link to this article: https://inheritedcancer.net/post121520/
Permanent link to this article: https://inheritedcancer.net/post121120/
Permanent link to this article: https://inheritedcancer.net/post120820/
ICARE Social Media Post December 2020
Broader Germline Testing for Urothelial Cancer
ICARE Social Media Post December 2020
Broader Germline Testing for Urothelial Cancer
The most common inherited form of urothelial cancers is Lynch Syndrome. However, a study showed that of 586 individuals with urothelial cancer, 80 had a mutation in an inherited cancer gene (14%). Mutations in several genes were observed; however, 𝙈𝙎𝙃2 and 𝘽𝙍𝘾𝘼2 were both significantly associated with urothelial cancer (odds ratio of 3.7). Confirmatory …
Permanent link to this article: https://inheritedcancer.net/post120420/
Permanent link to this article: https://inheritedcancer.net/post120120/
Permanent link to this article: https://inheritedcancer.net/post112720/
Permanent link to this article: https://inheritedcancer.net/post112420/
ICARE Social Media Post November 2020
ASCO Guideline Updates: Breast Cancer
ICARE Social Media Post November 2020
ASCO Guideline Updates: Breast Cancer
The American Society of Clinical Oncology (ASCO) published updated guidelines for the management of hereditary breast cancer for the following gene carriers: 𝘽𝙍𝘾𝘼1/2 • Consider breast-conserving therapy • Consider nipple-sparing mastectomy, if medically appropriate • Advanced breast cancer: ⫸ PARP inhibitors (olaparib, talazoparib) preferred over non-platinum single agent chemotherapy ⫸ Platinum agents are recommended …
Permanent link to this article: https://inheritedcancer.net/post112020/
Permanent link to this article: https://inheritedcancer.net/post111720/
Permanent link to this article: https://inheritedcancer.net/post111320/
ICARE Social Media Post October 2020
CDH1: Cancer Risks and Risk Management
ICARE Social Media Post October 2020
CDH1: Cancer Risks and Risk Management
Gene: 𝘾𝘿𝙃𝟭 Cancer Risks and Management per NCCN Genetic/Familial High-Risk Assessment: Breast/Ovarian/Pancreatic Version 1.2021 and Gastric Version 3.2020: 𝗪𝗼𝗺𝗲𝗻: Breast cancer risk: Elevated at 55% – Recommend annual mammogram starting at age 30; consider breast MRI with contrast starting at age 30. 𝗠𝗲𝗻 𝗮𝗻𝗱 𝗪𝗼𝗺𝗲𝗻: Stomach cancer risk: Elevated at 83% for women, and 67% …
Permanent link to this article: https://inheritedcancer.net/post103020/
Permanent link to this article: https://inheritedcancer.net/post102720/
ICARE Social Media Post October 2020
PTEN: Cancer Risks and Risk Management
ICARE Social Media Post October 2020
PTEN: Cancer Risks and Risk Management
Gene: 𝙋𝙏𝙀𝙉 Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Breast/Ovarian/Pancreatic Version 1.2021: 𝗪𝗼𝗺𝗲𝗻: Breast cancer risk: Elevated at 85% – Recommend annual mammogram starting at age 30-35 (or 5-10 years before the earliest known breast cancer in the family); consider breast MRI with contrast starting at age 30-35; consider …
Permanent link to this article: https://inheritedcancer.net/post102320/
Permanent link to this article: https://inheritedcancer.net/post102020/
ICARE Social Media Post October 2020
TP53: Cancer Risks and Risk Management
ICARE Social Media Post October 2020
TP53: Cancer Risks and Risk Management
Gene: 𝙏𝙋𝟱𝟯 Syndrome: Li-Fraumeni Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Breast/Ovarian/Pancreatic Version 1.2021: 𝗪𝗼𝗺𝗲𝗻: Breast cancer risk: Elevated at 54% – Recommend clinical breast exam every 6-12 months starting at age 20, annual breast MRI with contrast starting at age 20, and annual mammogram starting at age 30; …
Permanent link to this article: https://inheritedcancer.net/post101620/
ICARE Social Media Post October 2020
New ASCO Guidelines On Use Of PARP Inhibitors To Manage Ovarian Cancer
ICARE Social Media Post October 2020
New ASCO Guidelines On Use Of PARP Inhibitors To Manage Ovarian Cancer
New guidelines for the use of PARP inhibitors to treat ovarian cancer among those with BRCA1 or BRCA2 mutations were published through the American Society of Clinical Oncology (ASCO) to guide providers about the role of this class of drugs in the management of this type of cancer. Link to the guidelines are available at: …
Permanent link to this article: https://inheritedcancer.net/post101320/
ICARE Social Media Post October 2020
CHEK2: Cancer Risks and Risk Management
ICARE Social Media Post October 2020
CHEK2: Cancer Risks and Risk Management
Gene: 𝘾𝙃𝙀𝙆2 Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Version 1.2020 & Breast/Ovarian/Pancreatic Version 1.2021: 𝗪𝗼𝗺𝗲𝗻: Breast Cancer Risk: Elevated at 28-44% – Recommend annual mammogram starting at age 40 and consider annual breast MRIs with contrast starting at age 40. 𝗠𝗲𝗻 𝗮𝗻𝗱 𝗪𝗼𝗺𝗲𝗻: Colorectal Cancer Risk: Elevated …
Permanent link to this article: https://inheritedcancer.net/post100920/
ICARE Social Media Post October 2020
Addition of Veliparib to Carboplatin/Paclitaxel in Previously Treated Patients With BRCA-Mutated Advanced Breast Cancer
ICARE Social Media Post October 2020
Addition of Veliparib to Carboplatin/Paclitaxel in Previously Treated Patients With BRCA-Mutated Advanced Breast Cancer
Among BRCA carriers with metastatic breast cancer, the combination of veliparib AND chemotherapy with platinum-based agents (carboplatin) and taxanes (paclitaxel) led to a longer duration of progression free survival (disease that did not progress), compared to those treated with ONLY chemotherapy. To read the full article visit: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30447-2/fulltext [This finding was previously outlined last year …
Permanent link to this article: https://inheritedcancer.net/post100620/
ICARE Social Media Post October 2020
ATM: Cancer Risks and Risk Management
ICARE Social Media Post October 2020
ATM: Cancer Risks and Risk Management
Gene: 𝘼𝙏𝙈 Cancer Risks and Management (per NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Version 1.2021) 𝗪𝗼𝗺𝗲𝗻: Breast cancer risk: Elevated at 30% – Recommend annual mammogram starting at age 40 and consider annual breast MRIs starting at age 40. Ovarian cancer risk: Possibly increased, not well established – Manage based on family history. …
Permanent link to this article: https://inheritedcancer.net/post100220/
ICARE Social Media Post September 2020
Living with Lynch 2020 Virtual Patient Workshop
ICARE Social Media Post September 2020
Living with Lynch 2020 Virtual Patient Workshop
SJoin the Colon Cancer Coalition and AliveAndKickn for the Living with Lynch 2020 Virtual Patient Workshop on𝗙𝗿𝗶𝗱𝗮𝘆, 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟵𝘁𝗵 𝗳𝗿𝗼𝗺 𝟭𝗽𝗺-𝟱𝗽𝗺 𝗘𝗧 to hear unique patient perspectives and the latest information from experts on Lynch syndrome. Visit https://www.livingwithlynch.org/2020-living-with-lynch to register for this free workshop today!
Permanent link to this article: https://inheritedcancer.net/post92920/
ICARE Social Media Post September 2020
AACR Cancer Disparities Progress Report 2020
ICARE Social Media Post September 2020
AACR Cancer Disparities Progress Report 2020
The American Association for Cancer Research (AACR) published a Cancer Disparities Progress Report. “… our limited knowledge of cancer biology in racial and ethnic minorities, including their inherited cancer predisposition and the genomic underpinnings of cancer initiation and progression, diminishes the potential of precision medicine in these populations.” This report discusses relevant information about inherited …
Permanent link to this article: https://inheritedcancer.net/post92520/
Permanent link to this article: https://inheritedcancer.net/post91820/
ICARE Social Media Post September 2020
ICARE Summer 2020 Newsletter
ICARE Social Media Post September 2020
ICARE Summer 2020 Newsletter
The ICARE Summer 2020 Newsletter is now available! Check out this latest edition for recent research and clinical updates as well as a Q&A with a nationally renowned clinical geneticist from Vanderbilt-Ingram Cancer Center. You can read the newsletter by visiting: https://inheritedcancer.net/wp-content/uploads/ICARE-2020-Summer-Newsletter.pdf Please feel free to share with family members, friends, and/or your …
Permanent link to this article: https://inheritedcancer.net/post91620/
ICARE Social Media Post September 2020
NCCN Genetic Testing Criteria Updates by Cancer
ICARE Social Media Post September 2020
NCCN Genetic Testing Criteria Updates by Cancer
The National Comprehensive Cancer Network (NCCN) released new guidelines on September 8th, 2020, which included updates to genetic testing criteria by cancer type as follows: Breast Cancer: Broadened to include relatives with ALL grades of prostate cancer (not just high-grade) Now having multiple breast cancer diagnoses is NOT dependent on whether the diagnoses were …
Permanent link to this article: https://inheritedcancer.net/post91520/
Permanent link to this article: https://inheritedcancer.net/post91420/
ICARE Social Media Post September 2020
NCCN Genetic Testing Choice Updates
ICARE Social Media Post September 2020
NCCN Genetic Testing Choice Updates
The National Comprehensive Cancer Network (NCCN) released new guidelines on September 8th, 2020, which included updates to genetic testing choices and considerations as follows: Choice of multi-gene panel may be guided by genes included, analyses offered, and financial assistance programs available for family testing Significant limitations in interpretations of polygenic risk scores: NOT recommended for …
Permanent link to this article: https://inheritedcancer.net/post91120/
Permanent link to this article: https://inheritedcancer.net/post91020/
ICARE Social Media Post September 2020
ACMG Guidelines for Genetic Testing for All Breast Cancer
ICARE Social Media Post September 2020
ACMG Guidelines for Genetic Testing for All Breast Cancer
Check out Vanderbilt’s article about genetic testing considerations at: https://discover.vumc.org/2020/02/genetic-testing-considerations-for-breast-cancer-patients/ Check out the original document from the American College of Medical Genetics and Genomics at: https://www.nature.com/articles/s41436-019-0712-x
Permanent link to this article: https://inheritedcancer.net/post90820/
ICARE Social Media Post September 2020
GREM1 Duplication
ICARE Social Media Post September 2020
GREM1 Duplication
The GREM1 gene leads to hereditary mixed polyposis syndrome, characterized by multiple polyps of mixed pathology and high risks for colorectal cancer. A specific duplication in the 5′ regulatory region of the GREM1 gene has been found in a subset of Ashkenazi Jewish individuals with hereditary mixed polyposis syndrome; therefore, GREM1 genetic testing is …
Permanent link to this article: https://inheritedcancer.net/post90420/
ICARE Social Media Post September 2020
Biallelic Mutations in BRCA1 Cause Fanconi Anemia
ICARE Social Media Post September 2020
Biallelic Mutations in BRCA1 Cause Fanconi Anemia
BRCA1 is not typically thought to be one of the genes which cause Fanconi anemia. However, rare cases of individuals with biallelic BRCA1 mutations (mutations in both copies of the gene) have been reported. One case involved a woman who had breast cancer at age 23, and was born with multiple birth defects consistent with …
Permanent link to this article: https://inheritedcancer.net/post90120/
ICARE Social Media Post August 2020
Older Women with Breast Cancer Have Higher Risks of Ovarian and Other Cancers
ICARE Social Media Post August 2020
Older Women with Breast Cancer Have Higher Risks of Ovarian and Other Cancers
Among 4,500 post-menopausal women with breast cancer, 3.55% had a mutation in a gene associated with inherited breast cancer (3-fold higher than what was seen among women who were cancer-free). BRCA1/2 mutations were seen more frequently in women diagnosed with breast cancer at or below age 65 (2.21%) compared to those diagnosed after age 65 …
Permanent link to this article: https://inheritedcancer.net/post82820/
ICARE Social Media Post August 2020
Pheochromocytoma and Paraganglioma Genetic Testing
ICARE Social Media Post August 2020
Pheochromocytoma and Paraganglioma Genetic Testing
More than 40% of patients with pheochromocytoma or paraganglioma, regardless of age and family history, carry an inherited gene mutation. Given that gene mutation carriers may benefit from gene-specific cancer screening, all individuals diagnosed with one of these tumors should seek genetic counseling to discuss genetic testing options. Genes that predispose to pheochromocytoma and paraganglioma …
Permanent link to this article: https://inheritedcancer.net/post82520/
ICARE Social Media Post August 2020
Optimal Timing of Prophylactic Gastrectomy for CDH1 Carriers
ICARE Social Media Post August 2020
Optimal Timing of Prophylactic Gastrectomy for CDH1 Carriers
Individuals with a CDH1 mutation and classic personal and family history of diffuse gastric (stomach) cancer have a very high risk of developing and dying from stomach cancer, if they do not have preventive surgery to remove their stomach. A simulation study to assess prophylactic total gastrectomy (PTG; the removal of the stomach to prevent …
Permanent link to this article: https://inheritedcancer.net/post82120/
ICARE Social Media Post August 2020
MRI Surveillance Has Very Low Yield After Bilateral Mastectomy and Reconstruction
ICARE Social Media Post August 2020
MRI Surveillance Has Very Low Yield After Bilateral Mastectomy and Reconstruction
A study of 159 women, including BRCA carriers, who had bilateral mastectomy with reconstruction, underwent breast MRI screening. The results showed few women had detection of breast cancer through MRI, after their bilateral mastectomy. These results support the recommendation against screening MRI in women who have had bilateral mastectomy with reconstruction due to a diagnosis …
Permanent link to this article: https://inheritedcancer.net/post81820/
ICARE Social Media Post August 2020
Inherited Prostate Cancer Risk
ICARE Social Media Post August 2020
Inherited Prostate Cancer Risk
Over 600,000 men age 40 and older who were part of a family with at least three consecutive generations affected with prostate cancer were studied from the Utah Population Database. Findings from this study showed that: 36,000 had prostate cancer (5.9%) 2,500 had early-onset disease (7%) 4,000 had lethal disease (11.1%) 15,000 had clinically significant …
Permanent link to this article: https://inheritedcancer.net/post81420/
ICARE Social Media Post August 2020
CDC Resource for Free Breast Cancer Screening
ICARE Social Media Post August 2020
CDC Resource for Free Breast Cancer Screening
We are here to help! Our followers asked us to provide information about screening resources for women with hereditary breast cancer. We would like to make folks aware about a CDC program that provides free breast cancer screening for women who are uninsured and underinsured. Check out more information at: https://www.cdc.gov/cancer/nbccedp/
Permanent link to this article: https://inheritedcancer.net/post81120/
Permanent link to this article: https://inheritedcancer.net/post80720/
ICARE Social Media Post August 2020
Disparities in BRCA Counseling Across Diverse Populations
ICARE Social Media Post August 2020
Disparities in BRCA Counseling Across Diverse Populations
A recently published study based on data from our participants showed that few young Black women with breast cancer see a genetic counselor AND those with insurance are LESS likely to see a genetic counselor. For more information, check out the full study at: https://www.nature.com/articles/s41436-020-0762-0
Permanent link to this article: https://inheritedcancer.net/post80420/
Permanent link to this article: https://inheritedcancer.net/post80320/
Permanent link to this article: https://inheritedcancer.net/post73120/
ICARE Social Media Post July 2020
Updates to 2020 NCCN Genetic/Familial Colorectal Guidelines
ICARE Social Media Post July 2020
Updates to 2020 NCCN Genetic/Familial Colorectal Guidelines
The National Comprehensive Cancer Network (NCCN) released new guidelines for 2020 on July 21, 2020. The big changes included refining some of the risks for genes involved in Lynch Syndrome, and providing specific guidance about cancer screening that may slightly differ by gene. You can check out the full guidelines by creating a FREE account …
Permanent link to this article: https://inheritedcancer.net/post72420/
ICARE Social Media Post July 2020
Racial Inequalities in Genetics
ICARE Social Media Post July 2020
Racial Inequalities in Genetics
[ngg src=”galleries” ids=”1″ display=”basic_slideshow” arrows=”1″ show_thumbnail_link=”0″]It is important to talk about racial inequalities in healthcare as it affects the care received among Black patients. Through our research efforts, we not only want to address the issue of racism but also think about ways to make healthcare more equitable. A recently published study including our research …
Permanent link to this article: https://inheritedcancer.net/post72120/
ICARE Social Media Post July 2020
Breast Cancer Risks May be Higher in Women with Two CHEK2 Mutations Versus One CHEK2 Mutation
ICARE Social Media Post July 2020
Breast Cancer Risks May be Higher in Women with Two CHEK2 Mutations Versus One CHEK2 Mutation
A study comparing women with two CHEK2 mutations to one CHEK2 mutation showed that those with two mutations were: -more likely to get breast cancer (80.6% versus 41.2%) -more likely to be diagnosed at or below age 50 (61.3% versus 23.9%) -more likely to have a second breast cancer diagnosis (22.6% versus 8.1%) These findings …
Permanent link to this article: https://inheritedcancer.net/post71720/
ICARE Social Media Post July 2020
Individuals with a First-Degree Relative with Blood Cancer Are at Increased Risk for Blood-Related Cancer
ICARE Social Media Post July 2020
Individuals with a First-Degree Relative with Blood Cancer Are at Increased Risk for Blood-Related Cancer
Individuals with a first-degree relative (for example, parent, sibling, or child) with blood cancer, such as lymphoma, have a higher chance of being diagnosed with blood-related cancer (i.e., hematologic malignancy), according to a recent study. The risk to develop certain blood cancers depends on how closely related the relative is (e.g., higher risks for first-degree …
Permanent link to this article: https://inheritedcancer.net/post71420/
ICARE Social Media Post July 2020
BRCA1/2 and Other Gene Carriers with Breast Cancer Don’t Always Receive Recommended Treatment
ICARE Social Media Post July 2020
BRCA1/2 and Other Gene Carriers with Breast Cancer Don’t Always Receive Recommended Treatment
BRCA1/2 and other gene mutation carriers with early stage breast cancer are not always receiving cancer treatment as recommended by national guidelines. Even though more and more people have been tested for hereditary cancer over the years, using this information accurately to guide treatment has not been as successful. These findings highlight the need for …
Permanent link to this article: https://inheritedcancer.net/post71020/
ICARE Social Media Post July 2020
Pancreatic Cancer Can Run in Families
ICARE Social Media Post July 2020
Pancreatic Cancer Can Run in Families
Individuals with a family history of pancreatic cancer have a higher risk to develop pancreatic cancer. A recent study reported the following pancreatic cancer risks compared to the general population, based on relationship to an individual with pancreatic cancer: First-degree relative (e.g., parent, sibling, child) – 1.76 fold higher Second-degree relative (e.g., aunts, uncles, grandparents) …
Permanent link to this article: https://inheritedcancer.net/post70720/
ICARE Social Media Post July 2020
Community Spotlight: Mari-Lynn Slayton
ICARE Social Media Post July 2020
Community Spotlight: Mari-Lynn Slayton
In every ICARE Newsletter we feature an ICARE participant as a community spotlight. Our community spotlight in our Winter 2016 ICARE Newsletter is Mari-Lynn Slayton, who was found to have a PALB2 mutation after two breast cancer diagnoses. Check out her story at: https://inheritedcancer.net/community-spotlight/
Permanent link to this article: https://inheritedcancer.net/post70220/
ICARE Social Media Post June 2020
Advances in Treatment for Colorectal Cancer
ICARE Social Media Post June 2020
Advances in Treatment for Colorectal Cancer
On June 29, 2020, the FDA approved the use of Keytruda (pembrolizumab), as first-line treatment in unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer. Among people with Lynch syndrome, the risk for colorectal cancer (which often has microsatellite instability and/or mismatch-repair deficiency) is raised. Keytruda (pembrolizumab) showed to double the progression-free …
Permanent link to this article: https://inheritedcancer.net/post63020/
ICARE Social Media Post June 2020
Higher Chance of VUS Results in Minorities
ICARE Social Media Post June 2020
Higher Chance of VUS Results in Minorities
Asian, Hispanic, and Black women with breast cancer had higher rates of variants of uncertain significance (VUS) on genetic test results for hereditary cancer genes compared to White women with breast cancer according to a recent study. Check out the full article at https://link.springer.com/article/10.1007%2Fs13187-019-01646-8
Permanent link to this article: https://inheritedcancer.net/post62620/
ICARE Social Media Post June 2020
Community Spotlight: Kelly Frank
ICARE Social Media Post June 2020
Community Spotlight: Kelly Frank
June is cancer survivor month! In every ICARE Newsletter we feature an ICARE participant as a community spotlight. Our community spotlight in our Winter 2019 ICARE Newsletter is Kelly Frank, who was found to have a BRIP1 mutation after an ovarian cancer diagnosis. Check out her story at: https://inheritedcancer.net/community-spotlight/
Permanent link to this article: https://inheritedcancer.net/post62320/
ICARE Social Media Post June 2020
Advances in Treatment for BRCA-Mutated Triple Negative Breast Cancer
ICARE Social Media Post June 2020
Advances in Treatment for BRCA-Mutated Triple Negative Breast Cancer
In a study of 914 women with different breast cancer subtypes, overall pathologic complete response rates were: Higher in those with BRCA1/2 mutations (60.4% versus 46.7%) No differences were seen in those with mutations in other inherited cancer genes Among patients with triple-negative breast cancer, BRCA1/2 mutations had highest response rates to treatment in both …
Permanent link to this article: https://inheritedcancer.net/post61920/
Permanent link to this article: https://inheritedcancer.net/post61620/
ICARE Social Media Post June 2020
Advances in BRCA1/2 Breast Cancer Treatment
ICARE Social Media Post June 2020
Advances in BRCA1/2 Breast Cancer Treatment
Through a randomized phase 2 study (called the INFORM trial) among BRCA1/2 carriers with breast cancer, cisplatin was no better in inducing pathologic complete remission compared to AC. The pathologic complete remission rate was 18% for cisplatin and 26% for AC. Cisplatin is not better than other chemotherapy for induction therapy for breast cancers in …
Permanent link to this article: https://inheritedcancer.net/post61220/
ICARE Social Media Post June 2020
Community Spotlight: Christy Mattey
ICARE Social Media Post June 2020
Community Spotlight: Christy Mattey
In every ICARE Newsletter we feature an ICARE participant as a community spotlight. Our latest community spotlight in our Winter 2017 ICARE Newsletter is Christy Mattey, who was found to have a CHEK2 mutation after a breast cancer diagnosis. Check out her story at: https://inheritedcancer.net/community-spotlight/
Permanent link to this article: https://inheritedcancer.net/post60920/
ICARE Social Media Post June 2020
Advances in Treatment for Pancreatic Cancer: Cisplatin + Gemcitabine
ICARE Social Media Post June 2020
Advances in Treatment for Pancreatic Cancer: Cisplatin + Gemcitabine
In BRCA1/2 or PALB2 carriers with stage 3 or 4 pancreatic cancer, the combination of cisplatin + gemtricitabine with veliparib (a PARP inhibitor), did NOT seem to provide additional benefit over cisplatin + gemtricitabine alone. Through this phase 2 randomized control trial, response rates in both treatment arms were high with similar overall survival rates. …
Permanent link to this article: https://inheritedcancer.net/post60520/
ICARE Social Media Post June 2020
Community Spotlight: Terry Arnold
ICARE Social Media Post June 2020
Community Spotlight: Terry Arnold
June is Cancer Survivor Month! In every ICARE Newsletter we feature an ICARE participant as a community spotlight. Our latest community spotlight in our Summer 2017 ICARE Newsletter is Terry Arnold, who was found to have a BRCA1 mutation after a breast cancer diagnosis. Check out her story at: https://inheritedcancer.net/community-spotlight/
Permanent link to this article: https://inheritedcancer.net/post60220/
ICARE Social Media Post May 2020
Cancer Risk Management Among Female BRCA1/2, PALB2, CHEK2, and ATM Carriers in ICARE
ICARE Social Media Post May 2020
Cancer Risk Management Among Female BRCA1/2, PALB2, CHEK2, and ATM Carriers in ICARE
A new article was recently published based on data from BRCA1/2, PALB2, CHEK2, and ATM carriers in ICARE. Findings suggest potential overtreatment through risk-reducing surgery among women with pathogenic/likely pathogenic variants in breast cancer genes. This highlights the importance of promoting guideline-adherent, risk-appropriate care. Check out the full article at https://rdcu.be/b4mbg
Permanent link to this article: https://inheritedcancer.net/post52620/
ICARE Social Media Post May 2020
Advances in Treatment for Metastatic Prostate Cancer: Olaparib
ICARE Social Media Post May 2020
Advances in Treatment for Metastatic Prostate Cancer: Olaparib
On May 19, 2020 the FDA approved the use of olaparib (Lynparza) as treatment in BRCA and other gene carriers (homologous recombination repair genes) with metastatic castration-resistant prostate cancer who have been treated with enzalutamide or abiraterone. Link to full article: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer
Permanent link to this article: https://inheritedcancer.net/post52220/
ICARE Social Media Post May 2020
Advances in Treatment for Metastatic Prostate Cancer: Rucaparib
ICARE Social Media Post May 2020
Advances in Treatment for Metastatic Prostate Cancer: Rucaparib
On May 15, 2020 the FDA approved the use of rucaparib (Rubraca) as treatment in BRCA carriers with metastatic castration-resistant prostate cancer who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Link to full article: https://www.fda.gov/drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate
Permanent link to this article: https://inheritedcancer.net/post51920/
ICARE Social Media Post May 2020
MRI May Detect Breast Cancer Earlier than Mammograms
ICARE Social Media Post May 2020
MRI May Detect Breast Cancer Earlier than Mammograms
The National Comprehensive Cancer Network (NCCN) currently recommends an annual breast MRI and an annual mammography for high-risk women (lifetime breast cancer risk at or above 20%). Among women at high risk for breast cancer, MRI detected breast cancer at an earlier stage than mammograms. Women with BRCA1/2 and TP53 were NOT included in this …
Permanent link to this article: https://inheritedcancer.net/post51520/
ICARE Social Media Post May 2020
Advances in Ovarian Cancer Treatment for BRCA1/2 Carriers: Olaparib & bevacizumab
ICARE Social Media Post May 2020
Advances in Ovarian Cancer Treatment for BRCA1/2 Carriers: Olaparib & bevacizumab
On May 8, 2020 the FDA approved the use of olaparib (Lynparza) as first-line maintenance treatment in BRCA1/2 carriers (deleterious or suspected deleterious mutations) and/or a genomic instability, with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Link to full article: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary
Permanent link to this article: https://inheritedcancer.net/post51220/
ICARE Social Media Post May 2020
Advances in Ovarian Cancer Treatment for BRCA1/2 Carriers: Olaparib
ICARE Social Media Post May 2020
Advances in Ovarian Cancer Treatment for BRCA1/2 Carriers: Olaparib
In recognition of World Ovarian Cancer Day, we’d like to share some exciting results from a study of women with ovarian cancer and a BRCA mutation: In a recent phase III trial, olaparib (PARP inhibitor) showed improved response and progression-free survival compared with chemotherapy (without platinum) in BRCA carriers with platinum-sensitive relapsed ovarian cancer who …
Permanent link to this article: https://inheritedcancer.net/post50820/
ICARE Social Media Post May 2020
Advances in Treatment for Metastatic Prostate Cancer: Olaparib
ICARE Social Media Post May 2020
Advances in Treatment for Metastatic Prostate Cancer: Olaparib
Findings from a recent study showed that olaparib (PARP inhibitor) significantly improved progression-free survival in patients with BRCA1, BRCA2, or ATM genetic alterations. Benefits were also more broadly seen among patients with homologous recombination repair gene defects. Link to full article: https://www.nejm.org/doi/full/10.1056/NEJMoa1911440 Check out the ASCO post article at: https://www.ascopost.com/news/may-2020/olaparib-for-patients-with-mcrpc-and-homologous-recombination-repair-gene-alterations/
Permanent link to this article: https://inheritedcancer.net/post50620/
ICARE Social Media Post May 2020
CDH1: Gastric and Breast Cancer Risks
ICARE Social Media Post May 2020
CDH1: Gastric and Breast Cancer Risks
CDH1 mutation carriers are at higher risk for diffuse gastric cancer (men and women) and lobular breast cancer (women). Current strategies to manage high risks of gastric cancer include prophylactic gastrectomy (i.e., removal of the stomach), which can have severe physical and psychological implications. A recent study found that men have a higher risk of …
Permanent link to this article: https://inheritedcancer.net/post50520/
ICARE Social Media Post May 2020
New Blood Test May Find Ovarian Cancer Early
ICARE Social Media Post May 2020
New Blood Test May Find Ovarian Cancer Early
A study of 80 women identified 4 proteins in blood that may help to detect ovarian cancer early. Further research is still needed with larger groups of women to determine if this new blood test would be a reliable test to find ovarian cancer early. Check out the full article at https://www.nature.com/articles/s41416-019-0544-0
Permanent link to this article: https://inheritedcancer.net/post50120/
ICARE Social Media Post April 2020
Advances in Treatment for Ovarian Cancer in BRCA1/2 Carriers: Niraparib
ICARE Social Media Post April 2020
Advances in Treatment for Ovarian Cancer in BRCA1/2 Carriers: Niraparib
On April 29, 2020 the FDA approved the use of niraparib (Zeluja) as first-line maintenance treatment in BRCA1/2 carriers with advanced ovarian cancer! More details available at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer
Permanent link to this article: https://inheritedcancer.net/post42920/